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治療中，結果顯示’ 1 molkg'i劑量的BAM-SiPc能顯著地殺死(肝癌腫瘤，HepG2) 
或抑制(腸癌腫瘤，HT29)的癌細胞腫瘤的生長。 
H&E肝臟染片及血清蛋白酶(ALT, AST, CK)活性測示的結果顯示，以 
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Photodynamic therapy (PDT) has been found to be useful in many different 
applications with its anti-fungal, anti-microbial and anti-cancer activities. As serious 
side effects such as skin photosensitivity have been reported for those patients 
administered with Photofrin®, it is necessary to search for alternate photosensitzer 
that exhibits high photodynamic activities but with minimal side effect. 
Recently, a novel series of silicon(IV) phthalocyanine derivatives has been 
synthesized. Among the series, BAM-SiPc, an unsymmetrical bisamino silicon(IV) 
phthlocyanine, was identified as a promising photosensitizer with an extremely high 
phototoxicity toward different cancer cell lines. The IC50 was in nano-molar 
concentration. 
In the biodistribution study, it was found that BAM-SiPc could be almost 
cleared (〜98o/o) from the nude mice one week after injection. Persistent 
accumulation of BAM-SiPc in tumor was shown even for 24 hr after BAM-SiPc 
administration. However, there was no selective uptake of BAM-SiPc in HepG2 
tumor. Significant tumor regression (HepG2) or growth inhibition (HT29) was 
observed after in vivo PDT with 1 ^ imolkg"' of BAM-SiPc. H & E staining of the 
liver section and assay of plasma enzyme activities (ALT, A S T and CK) showed that 
no hepatic or cardiac injury was induced by the protocol used in this study. 
For the metabolism of BAM-SiPc, it was found that BAM-SiPc could be 
metabolized by the normal liver cells WRL-68 but not by HepG2 cells. When B A M -
SiPc was incubated with the mice liver homogenate, there was a time-dependent 
decrease in BAM-SiPc content. The metabolite was found to be non-toxic both in the 
dark and in the presence of light. 
V 
Mstract 
There was a dose-dependent increase of intracellular R O S production when 
cancer cells were PDT-treated with BAM-SiPc. In the cell cycle analysis, arrest in 
Go/Gl phase was observed when HepG2 cells were PDT-treated with BAM-SiPc at 
concentration ranging from 0.005 f^ M to 0.02 )liM. Apoptosis was induced in HepG2 
tumor after in vivo P D T with BAM-SiPc as shown by the result of Terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and H & E 
staining of the tumor sections. 
Finally, it was shown that the PDT efficacy of BAM-SiPc decreased in the 
presence of LDL. Cellular uptake of BAM-SiPc was inhibited by LDL. However, 
L D L conjugated BAM-SiPc could not be identified by gel filtration. Therefore, the 
reason for the decrease in BAM-SiPc uptake has yet to be determined. 
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Cfiupter 1 Introduction 
CHAPTER 1 
Introduction 
1.1 History and development of photodynamic therapy 
Photodynamic therapy (PDT) is a treatment which combines the administration 
of photo-reactive agent and illumination on target area to remove the unfavourable 
tissues. Its medical value could be dated back to ancient Egypt and India. At that time, 
a photosensitive chemical called psoralens, extracted from some seeds and fruits, was 
utilized to treat some skin diseases】. However, the medical value of PDT was not 
realized in the modern era until the beginning of century. Nieis Finsen won the 
Nobel Prize for his work on using "phototherapy" to treat smallpox and tuberculosis^ . 
Later, Herman von Tappeiner and A. Jesionek have successfully treated tumors on 
skin by activating the topical eosin with sunlight�，Despite the promising discovery 
of the anti-cancer effect of PDT, the use of photosensitizers (PS) was better known 
for the photo-detection of tumor tissue because of the fluorescent property of PS^ 
Until 1960s and 1970s, Lipson et al. ^ and Dougherty^ used hematoporphyrin 
derivatives (HpD) and fluorescein respectively to destroy tumor tissue. Since then, 
PDT has been studied extensively, including the basic mechanism of PDT-induced 
cytotoxic effect, formulation of novel PS or PS derivatives and most importantly the 
medical application of this mode of treatment. Particularly, the anti-cancer activity of 
PDT has drawn the most of the attention from the researchers. In the late 1990s, 
Porfimer Sodium or commercially called Photofrin® (Fig. 1.1 a), a purified version of 
HpD, was approved for clinical use in United States and Canada. Photofrin® was 
found to be useful in treating early and late-stage lung cancer and also esophageal 
cancer^. Since then, several more PS, for example, methyl-tetrahydroxyphenyl 
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Fig. 1.1 Chemical structures of some photosensitizers used in photodynamic 
therapy: (a) Photofrin®, (b) Benzoporphyrin derivatives, (c) Foscan® and (d) 
Phthalocyanines. 
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chlorine (Temoporfm or Foscan®), 5-aminolevulinic acid (5-ALA), methyl 
5-aminolevulinate, etc. have been approved for clinical use in different countries (e.g. 
U.S.A. and Canada). 
1.2 Basic principle of photodynamic therapy: the beauty of the 
treatment 
• Oxidation as a potent killing weapon 
PDT can kill cells rapidly because it can greatly increase the intracellular 
oxidative pressure. The sudden increase in oxidative stress will trigger a cascade of 
death signaling events inside the cells. Such oxidation is accomplished by a cascade 
of the energy transferring processes. There are two types of photo-oxidation reaction, 
Type I and Type II photoreaction. In an anoxic or hypoxic intracellular environment, 
Type I photoreaction will dominate which means that the excited PS will directly 
oxidize an organic substrate (e.g. plasma membrane components). The reduced PS 
will further react with oxygen molecules to produce reactive oxygen species (ROS) 
such as superoxide anion and hydroxyl radical (OH.). ROS is such a highly reactive 
free radical that its oxidative power can cause serious intracellular damage, leading 
to cell death. However, in most cases, the Type II photoreaction is the dominant type 
in PDT, which means the energy of the excited PS will be transferred to molecular 
oxygen and produce an extremely reactive substance, singlet oxygen which is 
believed to be the key cytotoxic agent during PDT^ (Fig. 1.1). 
As singlet oxygen is highly reactive, it has a very short life time ranging from 
10-100 )as. The oxidative damage towards the cells will only be confined within a 
small region and within an individual cell because singlet oxygen can only travel a 
very short distance. 
3 
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Fig. 1.2 Schematic diagram showing the basic principle for the generation of 
ROS. 
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• Light delivers highly specific and localized therapy 
PDT consists of two non-cytotoxic components, light and PS. Singlet oxygen 
will only be produced when light is delivered to excite the PS. By virtue of this 
property, photodynamic effect can be localized to the target area simply by 
manipulating the light source. Currently, surgery, radiotherapy and chemotherapy are 
the major treatments for cancer. However, different degrees of side effects had been 
reported in patients who received these treatments. 
Surgery involves the removal of a large part of the organ and takes a very long 
time for patients to recover. Situations would become more complicated for those 
patients who suffered from advanced stage or late stage cancers. Chemotherapy is 
usually used as a last resort to control the progress of the disease, but a great 
discomfort has to be tolerated by the patient because of the non-discriminative 
cytotoxic effect on both normal and cancer cells. In radiotherapy, there is a limiting 
dose for application on each patient because of its carcinogenic effect. Due to these 
drawbacks of the other treatments, PDT emerges as a very attractive alternative. 
Endoscope equipped with optical fibers is commonly used for delivering light to 
activate the PS when the target tissue is located deep inside the body^. Recently, 
Moseley et al. ^ has introduced a novel device called "sticking plaster" which makes 
application of PDT more convenient and without time-constraint. "Sticking plaster" 
is actually a portable light emitting diode array which can be placed firmly on the 
target area of the patient. This allows the continuous activation of the PS which has 
been smeared on the skin surface. It has been proved to be effective in treating 
superficial basal cell carcinoma and actinic keratosis. 
5 
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1.3 Photosensitizers: From discovery, synthesis to modifications 
The discovery of photodynamic activity was rather accidental. After Lipson et 
al. 6 had recognized the anti-tumor activities of HpD, many researchers started to 
search or synthesize new PS for application on cancer treatment. After decades of 
experience, it is widely accepted that an ideal photosensitizer should fulfill several 
basic criteria: 
1. Cytotoxicity should only be exerted with light activation but the PS should remain 
non-toxic in the dark. 
2. PS with an absorption maximum (excitation wavelength) at a wavelength greater 
than 600 nm is preferred because red light or light with wavelength near the 
infra-red region can penetrate deeper into the skin. 
3. PS should preferentially accumulate in tumor tissue rather than normal tissue and 
singlet oxygen can be effectively generated in the target cells. 
Throughout the decades of investigation, many different kinds of PS have been 
reported to be potential photosensitizing agents. HpD (first generation PS), chlorins, 
cacteriochlorins and phthalocyanines (second generation PS) are highly valued 
compounds in various applications. Photofrin®, the first clinically approved PS, was 
thought to be a promising agent because it could effectively treat oncological 
diseases such as advanced stage of lung cancer. However, there were also many 
reports stating the drawbacks of using Photofrin® which were not expected at the 
very beginning. 
Skin photosensitivity is the most adverse and significant side effect suffered by 
the patients who received Photofrin®- PDT. Some clinical reports suggested that the 
selectivity of Photofrin® to tumor tissue was low and the drug could be retained in 
the healthy tissue, especially skin, for up to several weeks or even months. Much 
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inconvenience arises because patients have to avoid sunlight or high intensity light 
during this period^ ' The wavelength of absorption maximum for Photofrin® is 
630 run. Only a relatively small portion of light at this wavelength can transmit 
through the skin to activate the PS. Another drawback is that patients have to wait for 
48-72 h and protect from light after administration of Photofrin® in order to allow 
selective accumulation of PS in tumor tissue before illumination can be applied. Due 
to these reasons, using Photofrin® for PDT is not a favourable choice which is why 
its prevalence has been limited. Therefore, searching for a better PS is still an 
ongoing task in the field of PDT. 
• Other commercially available PS: Benzophorphyrin derivatives and Foscan 
Benzoporphyrin derivative (BPD) (Fig. 1.1b) is photodynamically active with 
an absorption maximum around 690 nm. However, it is not suitable for cancer 
treatment because it is rapidly cleared from the body, only 3 hours after intravenous 
administration. Also, the tumor selectivity is relatively low'^ Nevertheless, 
Verteporfm, one of the BPDs，was found to be effective in destroying the 
neovasculature on the retina and has been approved for clinical use in treating 
age-related macular degeneration'^ ' 
A commercially available PS called Foscan® (Fig. 1.1c) has been used in 
treating palliative head and neck cancer. It is the most active PS among the series of 
tetrahydroxyphenyl analogues with an excitation wavelength at 652 nm. In terms of 
photodynamic efficacy, Foscan® is better than Photofrin® as it can produce similar 
extent of cellular damage with a lower drug and light dose'^ (Foscan®: -0.1 mg/kg, < 
20 J/cm^; Photofrin: 2 mg/kg,〜200 J/cm^). However, the unusual high phototoxicity 
of Foscan® has made the optimization of treatment protocol very difficult. Also, large 
7 
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lesion would be left for those patients who have received the treatment. Skin 
photosensitivity could still be suffered 20 days after PS administration'^ These make 
the choice of Foscan® as a photo-activating agent unfavourable in some 
circumstances. 
• Phthalocyanines 
Phthalocyanine (Pc) is another class of PS which has gained much attention. 
Similar to hematoporphyrin, phthalocyanine possesses a tetra-pyrrolic ring (Fig. l.ld) 
which allows PS excitation by light and results in the production of singlet oxygen. 
Physically, it has a longer wavelength of absorption maximum than Photofrin® at 
around 670 〜680 nm. A lower intensity of light can thus be used to activate the PS 
because light with longer wavelength can travel deeper under the skin. Metal 
chelation to the central core of the ring is often done in order to lengthen the time of 
the triplet excited state and hence the amount of singlet oxygen produced. 
Aluminum(III) phthalocyanines (AlPc), Zn(II) phthalocyanines (ZnPc) and 
Silicon(IV) phthalocyanines (SiPc or Pc 4) are examples of the Pc series of 
photosensitizer. In the last decade, the in vitro and in vivo photodynamic activities of 
Pc, especially for ZnPc and SiPc, have been intensively studied. One study has 
shown that significant tumor regression can be observed in a murine EMT-6 tumor 
bearing Balb/c mice model treated with fluorinated ZnPc derivatives'^ . Another study 
suggested that ZnPc may be effective in suppressing skin cancer activities by 
demonstrating the in vitro phototoxicity to three different skin-derived cell lines, 
namely, HT-1080 transformed human fibroblasts, 3T3 mouse embryo fibroblasts and 
HaCaT human keratinocytes'^ . Beside anti-cancer activity, ZnPc has also been 
1 o 
reported to be able to inactivate bacterial growth . 
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SiPc is one of the most photoactive PS among the Pc series. The usefulness of 
SiPc in cancer therapy has been reflected by its tumoricidal activities in a wide 
variety of cancer cells. George et al. ^^ suggested that Pc 4 could suppress the 
proliferation of glioma. They found that Pc 4 mediated PDT can induce apoptosis 
(low light dose) or necrosis (high light dose) of U87-derived human glioma in nude 
in 
rat as revealed in the histological study. Whitacre et al have revealed that there is a 
significant tumor regression when human colon cancer xenografts (SW 480) were 
treated with Pc 4 and illuminated with a diode laser of wavelength at 672 run. 
Colussi et al. has also found that Pc 4 was effective in eradicating human ovarian 
epithelial carcinoma (OVCAR-3) in nude mice. 
• Obstacles for PDT to gain popularity in medical field 
Currently, testing on phthalocyanines has already entered preclinical or Phase I 
clinical trial. Borgatti-Jeffreys et al ^^ used zinc phthalocyanine tetrasulfonate to 
successfully obtain complete or partial tumor regression response in mice and dogs 
with naturally occurring neoplasms. Although a lot of PS is available and some have 
already been approved for clinical use, adjusting the optimum drug and light doses to 
maximize treatment efficacy but with minimal side effect is still a very difficult issue 
to tackleio. One major reason is that the selective accumulation of PS in tumor tissue 
instead of healthy tissue is not apparent. To solve this problem, researchers have tried 
to synthesize derivatives of PS with high phototoxicity but low dark toxicity, 
examples included the BPD derivatives, ZnPc derivatives and SiPc derivatives. The 
PDT efficacy of the derivatives is better than their parental PS as modification of 
their chemical properties allows better diffusion into abnormal tissue. In recent years, 
attempts have been made to modify PS by conjugation with biomolecules so as to 
9 
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increase the selective uptake which is based on the biological properties of the target 
tissues. 
1.4 Enhancement of selective retention of PS in cancerous tissue 
PDT is an attractive therapeutic option for cancer treatment because it can exert 
cytotoxicity specifically by manipulating the light source. Also, it is believed that PS 
can selectively accumulate in the rapidly proliferating tissue especially the malignant 
cells. Such belief is based on the abnormal properties of malignant tissues including 
large interstitial space, a leaky vasculature, compromised lymphatic drainage and 
lower intracellular pH, etc. when compared with their normal counterpart. These 
properties facilitate the diffusion of PS especially those PS which are amphiphilic in 
nature'"*. However, some researchers has reported that there is actually no 
preferential uptake of PS by cancerous tissue compared to normal tissue. One typical 
example is Photofrin® where the PS is selectively taken up by the skin and causes 
photosensitivity with symptoms such as burn and skin rashes. 
• Amphiphilic PS is photodynamically more active than ordinary PS 
Molecules with both hydrophobic and hydrophilic regions at different positions 
are regarded as amphiphilic. The hydrophobic region and hydrophilic region of an 
amphiphilic PS can interact with the surrounding environment independently. So, it 
exerts greater phototoxicity on the target cells because amphiphilic PS can readily 
insert into the membrane structure or the surface of protein where oxidative attack 
and cell death can be rapidly produced^' Margaron et al ^^  suggested that the 
amphiphilicity of the tetraphenylporphine will increase with the number of sulfonic 
acid substitution. They found that the higher the amphiphilicity of 
10 
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tetraphenylporphine, the greater was the phototoxicity generated. Later，Cauchon et 
al. supported the same argument by substituting zinc trisulfophthalocyanines with 
an alknyl side chain. They found that substitution with hexynyl or nonynyl groups 
would increase the amphiphilicity of the compound which enhanced the cellular 
uptake, mitochondrial membrane insertion and potency of the PS. 
• Increase cell targeting by biological modification of PS 
Malignant cells usually possess abnormal biological properties which the normal 
cells do not have. Many researchers have designed modification of PS which can 
target those abnormal features in order to increase the PS uptake specificity. At the 
very beginning when such idea had just emerged, many researchers tried to conjugate 
PS with common biomolecules such as bovine serum albumin (BSA), low density 
lipoprotein (LDL) or saccharides to see whether there is any increase in PS uptake in 
tumor cells. Brasseur et al. ^ ^ has successfully demonstrated that B S A conjugation 
with AIPCS4 allows the drug to accumulate more in the cancer cells. As a result, the 
phototoxicity towards J774 mouse mammary tumor cells of monocyte-marcrophage 
origin can be significantly increased. In addition, they found that maleyated B S A 
conjugation could further enhance the photodynamic activity because the negative 
charge on maleyated B S A could increase the binding of the conjugated PS to 
scavenger receptor. Similar observation was also reported in the studies by Hamblin 
et al. and Huang et al. Hamblin et al showed that conjugating chlorine6 with 
maleylated B S A could enhance its phototoxicity towards J774 cells while Huang et 
al demonstrated that the phototoxic effect of B S A conjugated dicationic silicon(IV) 
phthalocyanine towards HepG2 hepatocarcinoma cells was greater than that of the 
unconjugated PS. 
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Lipoproteins, especially LDL, is another class of biomolecule where the 
efficiency in increasing selective uptake of PS by tumor cells has been cited in many 
reports. It is believed that LDL conjugation can increase the selective uptake mainly 
through L D L receptor recognition. The role of L D L receptor in enhancing PS uptake 
has been studied by using human and rat transformed fibroblasts. The results showed 
that both Hematoporphyrin-LDL and ZnPc-LDL conjugated complexes were 
accumulated more than the unconjugated PS. The L D L conjugated Hp was 
internalized through L D L receptor uptake whereas the L D L conjugated ZnPc entered 
the cells by non-specific endocytosis . When chlorine6 was covalently attached with 
L D L molecule, the cellular uptake was greater than those of free chlorine6 and 
non-covalently attached complex: 80% of the targeted cells was killed compared 
with only 10% by using the same amount of free or non-covalent complexed 
chlorine6^ .^ Although there are much evidence supporting that L D L conjugation can 
enhance the potency of a PS, many studies have only proved such idea in in vitro cell 
culture system. The usefulness of LDL conjugation in an in vivo or clinical system 
remained uncertain, van Lier et al. ^^ had even found that L D L conjugation could not 
significantly increase the phototoxicity of aluminum (dodecylaminosulfonyl) 
tetrasulfophthalocyanine in an animal model. Such phenomenon was thought to be 
due to the natural distribution of PS to LDL in the blood stream when intravenous 
injection was employed. On the other hand, they had also found that the 
photodynamic activity would be abolished after the covalent attachment of L D L to 
AIPCS4. It seems that the effect of L D L conjugation will vary depending on different 
PS, cell types or type of conjugation. Further studies are still required to confirm 
under what circumstances will LDL conjugation increase the potency of a PS. 
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• Other drug delivery systems to enhance PDT specificity 
In addition to LDL and serum albumin, molecules such as transferrin and steroids 
have also been reported to increase PS uptake in tumor cells�，. These modifications 
are based on the fact that malignant tissues have a higher demand of resources for 
maintaining cell integrity, cell division and energy production. Besides, some 
researchers have designed modifications which can manipulate the subcellular 
localization of PS. With the importance of singlet oxygen contributing to cell death 
and realizing that it can only travel within a short distance (~45 run), the subcellular 
localization of PS would be a key factor to determine the magnitude of PS 
photodynamic activities;;. Delivering PS to the cell nucleus is a promising approach 
in improving PDT specificity because nucleic acids are very photosensitive and their 
K o o 
damage will readily induce cell death. Akhlynina et al. ‘ tried to covalently 
attached chlorine6 with BSA and insulin molecule and found that chlorine6 would be 
localized to cell nucleus and produced significant phototoxcity to the cell. Later, they 
have also tried to link the bio-conjugated chloririee with a nuclear localization signal 
so as to facilitate the transport of PS to the nucleus through the nuclear pore complex. 
Results showed that the photodynamic efficacy of chlorine6 could be increased by 
more than 2400 fold. 
Recently, a novel approach to enhance PDT specificity has been developed. It 
involves the design of a PS covalently attached with a macromolecule such that the 
PS will only become activated when the macromolecule is cleaved away. This idea is 
similar to the concept of "magic bullet". PS attached with macromolecules such as a 
polypeptide will only become activated within tumor tissues where there is an 
over-expression of tumor-associated protease, for example, cathepsins and matrix 
metalloproteinase39-4i. These proteases can cleave away the polypeptide chain and 
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leave the free PS within the cancer cells. This method is called protease-mediated 
PDT42. 
Currently, many molecules have been identified to be useful in increasing the 
selective accumulation of PS. However, each bio-conjugation is only workable in 
several types of cell due to the diverse cellular characteristics between different kinds 
of cell. Moreover, each kind of PS was often reported to be effective in curing some 
diseases but not the other^ .^ Also, difficulty in optimizing the drug and light doses 
has not yet been solved. Therefore，there is still a need to look for a novel class of PS 
or PS derivatives. 
1.5 Development of silicon (IV) phthalocyanine (SiPc) derivatives 
Previously, we have investigated the in vitro photodynamic activities of a series 
of phthalocyanine derivatives. The compounds are mostly ZnPc derivatives and SiPc 
derivatives. Derivatives were synthesized aiming at improving tumor targeting and 
hence the P D T efficacy when compared with their parental PS. Derivatives were 
often formed by chemically replacing the substituent at the axial position with 
chemical groups or well-known biomolecules. These modifications can either alter 
the chemical properties of the parental PS (from hydrophobic / hydrophilic to 
amphiphilic) to facilitate the diffusion and accumulation of PS within malignant cells 
or the biomolecule can be selectively uptaken by malignant cells through 
receptor-mediated endocytosis. 
SiPc(py)2，SiPc(Gal)2, SiPc[C3H5(NMe2)20](0Me), SiPc[C3H5(NMe2)20]2 are 
members of a series of SiPc derivatives in which their in vitro photodynamic 
activities have been reported previously*^  (Fig. 1.3). The details of these compounds 
are as follows: 
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Fig. 1.3 Chemical structures of SiPc derivatives: a) SiPc(py)2; b) SiPc(Gal)2; 
c) BAM-SiPc; d) SiPc[C3H5(NMe2)20]2. 
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1. SiPc(py)2 : The axial positions of SiPc were symmetrically substituted with 
pyridine group. The pyridine groups mimic the structure of pyrimidine ring. This 
modification was designed based on the fact that malignant cells have an extra 
nucleotide demand for rapid D N A synthesis and cell proliferation. Selective 
uptake of the PS by cancer cells could be conferred by recognizing the 
substituent and endocytosed by the cancer cells. 
2. SiPc(Gal)2 : This derivative was axially substituted with two acetal-protected 
galactose groups symmetrically. As there is an over-expression of glucose 
transporter in tumor cells'^ "^^ '^ '斗〜such modification has been designed in a way to 
enhance the accumulation of PS in cancer cells through the glucose transporter 
uptake mechanism. On the other hand, the bulky acetal-protected galatose 
substituents would increase the hydrophilicity and inhibit the self aggregation of 
the PS''. 
3. SiPc[C3H5(NMe2)20](0Me) or BAM-SiPc: unsymmetrical substitution with 
l,3-bis(dimethylamino)-2-propoxy and methyl groups which make SiPc more 
amphiphilic in nature. This compound was believed to diffuse more readily 
across and insert into the membrane of the cell"^ .^ 
4. SiPc[C3H5(NMe2)20]2: the parental compound in the synthesis of BAM-SiPc. It 
was formed by the symmetrical axial linkage of two 
1,3-bis(dimethylamino)-2-propoxy groups. 
The IC50 (i.e. the concentration of drug that results in 50% cell viability) of 
SiPc(Gal)2，BAM-SiPc and SiPc[C3H5(NMe2)20]2 against the cultured cancer cells 
were found to be at nano-molar level using HepG2 and J774 as the cell models*〗’*?. 
In particular, BAM-SiPc appeared as the most potent PS. In this series of SiPc 
derivatives, amphiphilicity seems to play an important part to the phototoxicity of 
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PS. 
1.6 Death mechanisms in photodynamic therapy 
PDT can induce cell death either by necrosis because of the extensive cellular 
damage or by triggering the death signal and switch on the apoptotic pathway. Drug 
and light dose, subcellular localization of PS and cell type are the factors which 
control the mode of cell death'^ .^ There are two different pathways of apoptosis, the 
death-receptor mediated apoptosis (extrinsic pathway) and mitochondria-mediated 
apoptosis (intrinsic pathway). PDT can induce apoptosis by triggering either pathway. 
Ahmad et al. 49 reported that human epidermoid carcinoma A431 cells underwent 
apoptosis after photosensitization with Pc 4. They found that Pc 4 mediated PDT 
could transiently increase the level of cell surface Fas-receptor and Fas receptor 
binding ligand, FasL which play crucial roles in the induction of the extrinsic 
pathway. Moreover, multimerization of the Fas protein and binding of the Fas 
receptor with the adaptor molecule FADD (Fas associated protein with a death 
domain) were observed after Pc 4 mediated PDT. Such interaction is known to 
trigger the downstream pathway of apoptosis, i.e. the binding and proteolytic 
cleavage of pro-caspase 8. 
• BAM-SiPc triggers the intrinsic pathway of apoptosis by a direct mitochondrial 
action 
Lo et al. 46’ 47 have reported that BAM-SiPc is predominantly localized in 
mitochondria of HepG2 and HT29 cells. The death mechanism of PDT with 
BAM-SiPc was studied by using HepG2 cells as a model. Apoptosis was induced 
after BAM-SiPc mediated PDT, as shown by the result of the Terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and 
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Annexin V staining. In the same study, Western blot analysis revealed that there were 
release of cytochrome C from mitochondria to cytosol and cleavage of 
poly-ADP-ribose polymerase (PARP). This confirms that the P D T treated cells had 
undergone the intrinsic pathway of apoptosis. For the extrinsic pathway, 10 )j.M 
caspase 8 inhibitor z-IETD-fmk was used but it could not significantly inhibit the 
death of cells. This indicates that the extrinsic pathway could play at best a minor 
role in causing cell death in BAM-SiPc mediated PDT. Other results such as 
down-regulation of Bcl-2 and translocation of Bax from cytosol to mitochondria both 
shed light on the mechanisms which regulate the PDT-mediated apoptosis^ .^ 
However, there is only very limited information about the detail signaling pathway of 
how P D T rapidly triggers the death signal. 
1.7 Objectives of the present study 
According to the result of in vitro photodynamic activity assay of 
SiPc-derivatives, BAM-SiPc was the most potent PS among the series. Therefore, 
BAM-SiPc was chosen for further investigation. HepG2 and HT29 tumor bearing 
nude mice was employed as models to study the in vivo photodynamic efficacy of 
BAM-SiPc. Since tumor selectivity and skin photosensitivity due to persistent 
retention of a PS in skin tissue were the major issues concerned in using PDT, 
biodistribution of BAM-SiPc was performed so that the uptake of BAM-SiPc by the 
tumor as well as drug clearance could be determined. Haematoxylin and eosin (H & 
E) staining of the histological liver section and assay of plasma enzyme activities 
were performed in order to assess the level of intrinsic toxicity induced by 
BAM-SiPc mediated PDT and evaluate the safety use of BAM-SiPc in cancer 
therapy. 
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Although the usefulness of PDT has been known for decades, the death 
mechanism and the intracellular signaling events involved are still uncertain. The 
intracellular R O S production and cell cycle distribution of PDT-treated HepG2 cells 
were determined to get an insight into the detail of how the BAM-SiPc mediated 
PDT triggers apoptosis. Due to the fact that different kinds of PS and dosage of 
treatment will execute different pathways of cell death, H & E staining and in vivo 
T U N E L staining have been performed to see whether apoptosis has been triggered 
after in vivo P D T with BAM-SiPc. 
Apart from that, metabolism of BAM-SiPc was also studied so as to investigate 
whether BAM-SiPc could be metabolized by liver cells and to see whether the 
metabolite is toxic to the host. Finally, low density lipoprotein was used as a carrier 
for BAM-SiPc to see whether the uptake of BAM-SiPc by tumors and hence the PDT 
efficacy of BAM-SiPc could be further increased in the presence of LDL. 
With all these information, we can assess the potential of using PDT with 
BAM-SiPc for cancer treatment in clinical trial. 
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CHAPTER 2 
Materials and Methods 
2.1 Synthesis of BAM-SiPc 
SiPc[C3H5(NMe2)20](0Me)， BAM-SiPc, an unsymmetrical bisamino 
silicon(IV) phthalocyanine was kindly provided by Prof. Dennis K.R Ng from 
Department of Chemistry, The Chinese University of Hong Kong. The procedures of 
the synthesis were summarized as f o l i o M e O H was slowly added to the top of a 
solution of SiPc[C3H5(NMe2)20]2 (1.42 g, 1.71 mmol) in C H C I 3 . The bilayer system 
was left under ambient condition for 3 days. The precipitate formed was filter off and 
subjected to a basic alumina column (Merck, 70-230 mesh A S T M ) with 
CHCls/hexane (1:2) as the eluent to give a greenish blue solid (0.92 g, 75%) with 
RfCCHCls/hexane 1:2) =0.86. 
2.2 Preparation of BAM-SiPc solution for photodynamic treatment 
Solid BAM-SiPc was dissolved in dimethyl formamide (DMF) by means of 
ultrasonication. The concentration of the stock solution was adjusted to 800 fiM 
with reference to the standard curve obtained by spectrophotometric measurement. 
Then, the BAM-SiPc solution was diluted to 80 )liM with 0.01 M aqueous 
Cremophor EL (0.047 g in 1 ml of distilled water) as the solvent. The 80 ^iM 
BAM-SiPc was then diluted to 8 |iM and was sterilized by filtering through 0.2 ]im 
Acrodisc® Syringe Filters. The solution was finally diluted to appropriate 
concentrations with cell culture medium. Acrodisc® Syringe Filters (0.2 |j,m) with 
Supor® Membrane were purchased from Pall Gelman Laboratory, USA. D M F and 
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Cremophor EL were obtained from Sigma-Aldrich, USA. 
2.3 Cell line and culture conditions 
The human hepatocellularcarcinoma cells HepG2 and Hep3B, the human 
colorectal adenocarcinoma cells HT29 as well as the liver cells WRL-68 (Table 2.1) 
were originally obtained from American Type Culture Collection (ATCC). HepG2 
was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 
penicillin (50 units/ml) and streptomycin (50 i^g/ml) in 5% CO2, 95% air in a 
humidified incubator at 37°C. Hep3B, WRL-68 and HT29 were maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf 
serum, and penicillin-streptomycin (Penicillin, 100 units/ml; Streptomycin, 100 
|j.g/ml). Culture medium for HT29 was further supplemented with L-glutamine and 
transferrin to give a final concentration of 1.5 m M and 10 ^ ig/ml respectively. Fetal 
bovine serum, L-glutamine, penicillin-streptomycin solution, RPMI 1640 medium 
and D M E M were all purchased from Invitrogen Corporation, HK, Ltd while 
transferrin was obtained from Sigma-Aldrich, USA. 
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ATCC number Origin 
HepG2 HB-8065 Liver with hepatocelullar carcinoma 
Description: The cells demonstrate decreased expression of 
apoA-I m R N A and increased expression of catalase m R N A in 
response to gramoxone (oxidative stress). They express 
insulin-like growth factor II. There is no evidence of a 
Hepatitis B virus genome in this cell line. 
A T C C number Origin 
Hep3B HB-8064 Liver with hepatocellular carcinoma 
Description: This cell line contains an integrated hepatitis B 
virus genome. 
A T C C number Origin 
WRL-68 CL-48 HeLa contaminant 
Description: Cells contain Human Papilloma Viral D N A 
sequences and express some hepatocyte-like functional 
properties in culture. 
A T C C number Origin 
HT29 HTB-38 Colon with colorectal adenocarcinoma 
Description: The cells express urokinase receptors, but do not 
have detectable plasminogen activator activity. HT-29 cells 
are negative for CD4, but there is cell surface expression of 
galactose ceramide (a possible alternative receptor for HIV). 
The cell line is positive for expression of c-myc, K-ras, H-ras, 
N-ras，Myb, sis and fos oncogenes. 
Table 2.1 Properties of the cell lines used in the present study. 
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2.4 Animal tumor model 
Balb/c nude mice (20 - 25 g) were obtained from the Laboratory Animal 
Services Center (LASEC) at The Chinese University of Hong Kong. All experiments 
on tumor-bearing nude mice were approved by the Animal Experimentation Ethics 
Committee, The Chinese University of Hong Kong. In developing the tumor model, 
ten million tumor cells (HepG2 or HT29) were subcutaneously inoculated into the 
back of the nude mice (Fig. 2.1). Measurement of the tumor size was started on Day 
6 after tumor cells inoculation. Three parameters of the tumor, namely, length, width 
and thickness were measured by using the micrometer digital caliper (SCITOP 
Systems Ltd.). The tumor volume was calculated by the following formula: 
Tumor volume = n x (Length x Width x Thickness) / 6 
Mice were bred under pathogen-free condition with free access of food and water. 
2.5 PDT laser source 
Continuous wave laser was generated from the Ceralas PDT 675 medical laser 
system (bandwidth 675 nm 士 3 nm, power range 0.1 - 1 W ) coupled with a frontal 
light distributor (Fig. 2.2). This medical laser system and the frontal light distributor 
were purchased from CeramOptec GmbH, a company of Biolitec group, Germany. 
2.6 In vitro photodynamic activity assay 
2.6.1 Pr eparation of cells for photodynamic treatment 
Cells were seeded in 96-well plate at appropriate density (HepG2 and Hep3B: 
2 X 104 cells per well; HT29: 3 x lO* per well) and incubated overnight in a 5% CO2， 
95% air humidified incubator at 37 After incubation, the culture medium was 
removed and cells in each well were rinsed with 100 of phosphate buffer 
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Fig. 2.1 Tumor bearing nude mouse (9 days after inoculation). 
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Fig. 2.2 Setup of the PDT laser system. 
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saline (PBS, pH 7.4). One hundred ii\ of different concentrations of BAM-SiPc in 
culture medium was added. Samples were allowed to incubate in a 5% CO2, 95% air 
humidified incubator for 2 h at 37 Finally, solution in each well was aspirated and 
cells in each well were rinsed with 100 |al PBS. Samples were ready for illumination 
after filling with 100 of fresh culture medium per well. 
2.6.2 In vitro photodynamic treatment 
Cells treated with BAM-SiPc were illuminated with light for 10 min. The 
fluence rate for the illumination was 40 mWcm'^ such that an illumination of 10 min 
led to a total fluence rate of 24 Jcm"^. The illuminating set up consisted of a 300 W 
halogen lamp, a water tank for cooling and a color filter cutting off light with 
wavelength < 610 nm (Newport) (Fig. 2.3). After illumination, the cells were 
incubated in a 5% CO2, 95% air humidified incubator at 37 for 24 h to provide 
sufficient time for the recovery of the survived cells. After incubation, samples were 
ready for cell viability determination. 
2.6.3 Cell viability assay^^ 
The culture medium of the cell sample was aspirated. Cells were then washed 
with P B S and mixed with 50 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (3 mg/ml). Samples were allowed to 
incubate in a 5 % CO2, 95% air humidified incubator at 37 for 2 h. Afterwards, 
cells were lysed with 50 10% (w/v) sodium dodecyl sulphate (SDS) in 0.04 M 
hydrochloric acid in each well. The plate was then placed in a 60 oven for 30 min 
to lyse the cell and release the purple formazan crystal formed inside the viable cells. 
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^ ^ ^ ^ ^ ^ Light source 
C c f ) 
Water tank 




Fig. 2.3 Schematic diagram showing the set-up for illumination of the cancer 
cells. 
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Eighty |il of iso-propanol was then added to dissolve the formazan crystal. The 
samples were ready for spectrophotometric measurement. Absorbance at 540 run for 
each well was recorded by the ELISA plate reader (Bio-Rad). Percent cell viability 
was calculated by the following formula: 
% Cell Viability = [(OD540 treated s a m p l e - OD540 Blank)丨(OD540 c o n t r o l _ Blank)] X 100% 
SDS and M T T solid were USB products purchased from G E medical systems, H K 
Ltd. Iso-propanol was obtained from Sigma-Aldrich, USA. 
2.7 Determination of ROS production by 2',7'-dichIorofluorescein 
diacetate (DCFDA) assay 
R O S production was determined by using 2' ,7' -dichlorofluorescein diacetate 
(DCFDA). After PDT, the culture medium of the sample was aspirated and cells (2 
X 1 oVwell) were washed with PBS. One hundred fal of 100 |aM D C F D A solution in 
PBS was added to each well of cells and the mixture was allowed to incubate in a 5% 
CO2, 95% humidified incubator at 37 for 1 h in dark. Fluorescence 
measurements were then made in a fluorescence plate reader (TECAN Polarion, 
Tecan U K Ltd., Theale, U K ) using a 485 nm excitation filter and a 535 nm emission 
filter set at a gain of 60. D C F D A powder was purchased from Molecular Probes, CA, 
USA. 
2.8 Propidium iodide (PI) staining for analysis of cell cycle arrest 
HepG2 cells (1 x 10^) were seeded in 35 m m Falcon dish and allowed to grow 
overnight. After overnight incubation, the cell culture medium was aspirated and 
cells were rinsed with PBS, pH 7.4. Cells were taken for in vitro photodynamic 
treatment as described in Section 2.6.2. After the illumination, cells were further 
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incubated in the dark for 24 h. On the next day, cells were harvested by trypsinization 
and fixed with 70% ethanol at -20 °C for another 24 h. Afterwards, cells were 
pelleted by centrifugation at 1500 rpm for 3 min. Cell pellets were washed with PBS 
and resuspended in 1 ml PI staining solution (20 |Lig/ml PI, 8 j^ g RNase in PBS, pH 
7.4). Samples were further incubated for 15 - 30 min at 37 in the dark. Finally, 
cells were transferred for cell cycle analysis in the FASCanto Flow Cytometer (BD 
Biosciences, France). PI (crystal form) was purchased from Sigma-Aldrich, USA. 
RNase was purchased from Roche Diagnostics, Hong Kong Ltd. 
2.9 Biodistribution study of BAM-SiPc 
One lamol 0.7 mg) BAM-SiPc/kg of mice body weight was intravenously 
(i.v.) injected into the tumor-bearing nude mice. At different time intervals, the mice 
was anesthetized with an intra-peritoneal injection of 0.2 ml ketamine/xylazine 
cocktail solution (0.1 mg ketamine and 0.01 mg xylazine per gram of body weight; 
0.5 ml ketamine and 0.25 ml of xylazine were mixed with PBS to make a 5 ml 
cocktail solution). The major organs/tissues of the mice were excised, rinsed with 
PBS, pH 7.4 and blotted dry. The excised organs/tissues were homogenized with 
D M F by a Biospec Biohomogenizer (Fisher Scientific, USA). Homogenates were 
centrifuged at 2450 x g for 20 min to remove the large debris. Supernatants were 
collected and subjected to fluorescence measurement. The peak fluorescence 
intensity was recorded by scanning the fluorescence emission spectrum from 610 nm 
to 900 nm using an excitation wavelength at 608 nm. Amount of BAM-SiPc present 
in the sample was determined with reference to the standard curve. The amount was 
expressed in % initial dose (ID) per gram of tissue as calculated by the following 
formula. 
29 
CdapterZ ！MateriaCs ancCMethods 
% ID per gram of tissue = (amount of BAM-SiPc / weight of the tissue) ^  ^  
Initial injection dose ° 
Ketamine and xylazine solution were obtained from LASEC, The Chinese 
University of Hong Kong. 
2.10 In vivo photodynamic treatment 
In vivo photodynamic treatment was started on Day 9 after tumor cells 
inoculation. By that time, the tumor has reached a size of 40 m m ^ to 100 mm^. One 
|imol BAM-SiPc/kg of body weight was i.v. injected into the tumor-bearing nude 
mice as described in Section 2.9. Twenty-four hour after the injection, the nude mice 
were anesthetized with the ketamine / xylazine cocktail solution. PDT laser was 
directly spotted onto the tumor with a fluence rate of 0.1 Wcm'^ for 300 sec, giving a 
total fluence of 30 Jcm"^. Tumor sizes of the nude mice were followed for the next 15 
days. 
2.11 Assay for plasma enzyme activities 
Blood was obtained by intra-cardiac puncture. Heparin (1250 USP units/ml) 
was added to prevent blood coagulation. The blood samples were centrifuged at 4000 
rpm for 5 min to obtain the supernatants which represent the plasma. The activities of 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatine 
kinase (CK) were assayed by the commercially available assay kits. In the assay of 
ALT and A S T activities, 50 |li1 of plasma was allowed to incubate with 1 ml of assay 
reagent for 1 min at 37 Enzyme activities were then determined by monitoring 
the absorbance change at 340 nm for 2 min. To assay C K activity, 50 |j,l of plasma 
was allowed to incubate with 1 ml of assay reagent for 3 min at 37°C. Similarly, 
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enzyme activity was determined by monitoring the absorbance change at 340 nm for 
2 min. The amount of enzyme activity was expressed as U/L. ALT and AST enzyme 
activities assay kit were Infmity^^ products purchased from Thermo Electron 
Corporation, Australia while C K enzyme activity assay kit was the product of 
Biosystems，Spain. Heparin was purchased as the sodium salt which was the product 
of Sigma-Aldrich, USA. 
2.12 Determination of cellular uptake ofBAM-SiPc 
HepG2 cells (1 x 10^ ) were seeded in 35 m m Falcon dish and allowed to 
incubate overnight in a 5% CO2, 95% air humidified incubator at 37°C. After that, 
cells were incubated with 0.5 juM BAM-SiPc in RPMI medium. At different time 
intervals, cells were washed with PBS, pH 7.4 to remove the unbound BAM-SiPc. 
Cells were then harvested by trypsinization. Cells were washed twice with PBS and 
then lysed in D M F so as to release BAM-SiPc from the cells. Cells debris was 
removed by centrifugation at 2450 x g for 20 min. The amount of BAM-SiPc present 
inside the cells was determined by measuring the peak fluorescence intensity as 
described in Section 2.9 with reference to the standard curve of BAM-SiPc. The 
BAM-SiPc content was expressed in nmol per million of cells. The number of cells 
was counted under the bright-field microscope with the aid of a hematocytometer. 
Falcon dish was the product from B D Bioscience, France. 
2.13 Metabolism ofBAM-SiPc 
2.13.1 Comparsion between normal liver cells WRL-68 and the hepatocarcinoma 
HepG2 cells in their ability to metabolize BAM-SiPc 
HepG2 cells (1 x 10^) and WRL-68 cells (3 x 10^) were seeded in 35 m m 
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Falcon dish. After overnight incubation, cells were treated with 1 ml of 0.5 |j,M 
BAM-SiPc in respective cell culture medium for 2 h during which cells could 
maximally accumulate BAM-SiPc. BAM-SiPc solution was then removed from the 
cells and the dish was re-filled with fresh culture medium. After that, samples were 
allowed to incubate in a 5 % CO2, 95% air humidified incubator at 37 for 24 h to 
allow the cells to metabolize BAM-SiPc. The residual amount of BAM-SiPc was 
determined by the methods described in Section 2.9. 
2.13.2 Catabolism of BAM-SiPc by mice liver homogenate 
Liver was homogenized with 10-fold (w/v) PBS by using a Tissue Tearor on 
ice. The homogenate was then centrifuged at 2450 x g for 20 min to remove the large 
debris. Approximately 7 m g (protein content as determined by Bradford assay) of 
liver homogenate was mixed with BAM-SiPc such that the latter concentration was 8 
|j.M. Samples were then incubated at 37 for different periods of time. After that, 
samples were mixed in a 1:1 (v/v) ratio with D M F in order to extract the metabolite. 
The protein content was removed by centrifugation at 2450 x g for 20 min. 
Supernatants were collected and subjected to in vitro photodynamic activity assay 
(Section 2.6) after serial dilution with the RPMI cell culture medium. Residual 
amount of BAM-SiPc was determined by scanning the absorption spectrum from 610 
nm to 800nm. The reading at the absorbance peak (674 nm) was taken for 
calculation. 
2.14 Histochemical staining 
2.14,1 Preparation of paraffin-embedded tissue section 
Liver and tumor excised from the nude mice were fixed in 4 % 
paraformaldehyde, pH 7.4 overnight at 4 On the next day, tissues were processed 
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by Standard protocol for preparing histological section and embedded in paraffin. 
Tissue sections were cut with a thickness of 5 |Lim and then placed on 24 x 50 m m 
microscopic slides. The sections were allowed to dry completely by incubating in a 
60 oven. After overnight incubation, the sections were dewaxed and rehydrated by 
immersing in xylene solution and a series of alcohol solutions of descending 
concentration from 100% down to 70% before proceeding for further histochemical 
staining. 
2.14.2 Haematoxylin and Eosin (H & E) staining 
After dewaxing and rehydration, the paraffin embedded tissue sections were 
immersed in a 5 % Mayer's Haematoxylin solution for 2 min to stain the cell nuclei 
with purple colour. Sections were then washed in running water to remove the excess 
staining solution. After that, sections were immersed in 2 % Eosin for 5 min to 
counter-stain the cytoplasm with pink color. Tissue sections were immersed in a 
series of alcohol of ascending concentration from 70% to 100% and finally in xylene 
solution in order to dehydrate the sections completely. The stained tissue sections 
were finally mounted with a coverslip and viewed under the bright field of a Zeiss 
Axioskop II Plus microscope. Images were captured by the coupled AxioCam digital 
camera. 
2.14.3 Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) assay for studying apoptosis 
After dewaxing and rehydration with alcohol, the paraffin embedded tissue 
sections were taken for the detection of D N A strand breaks by the T U N E L assay. The 
experimental procedures were similar to that described in the protocol of In Situ Cell 
Death Detection Kit, Fluorescein (Roche Diagnostics, H K LTD). Briefly, tissue 
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sections were first immersed in freshly prepared permeabilization solution (0.1% v/v 
Triton X-100, 0.1% w/v sodium citrate) at room temperature for 8 min in order to 
inactivate any nuclease which could lead to false positive results. Sections were then 
rinsed twice with PBS, pH 7,4. The area around the samples was dried thoroughly. 
Fifty of T U N E L reaction mixture (terminal deoxynucleotidyl transferase and 
nucleotide mixture) provided in the kit was added to cover the whole tissue section. 
Sections were then incubated at 37 in humidified incubator for 60 min. After the 
incubation, sections were rinsed with PBS for 3 times. At this moment, the samples 
were ready for examination under the Fluorescence module of Zeiss Axioskop II Plus 
microscope with excitation wavelength 450-500 nm and emission wavelength 
ranging from 515-565 nm. Images were captured by the coupled AxioCam digital 
camera. Green fluorescence colour indicates positive staining of the cells. 
2.15 Conjugation of BAM-SiPc with LDL^' 
2.15.1 Analysis of the phototoxicity and cellular uptake of BAM-SiPc in the 
presence of LDL 
Human plasma low density lipoprotein L D L was mixed with BAM-SiPc at 
different ratio in serum-free RPMI 1640 medium. The mixture was incubated in the 
dark for 90 min at 37 °C with constant agitation. After that, one hundred of 
LDL-BAM-SiPc mixture was added to HepG2 cells (2 x per well) in each well. 
In vitro photodynamic activities assay were carried out as stated in Section 2.6.2. In 
cellular uptake experiment, 0.2 nmol of BAM-SiPc was mixed with 2 nmol of L D L 
and allowed to incubate with HepG2 (1 x 10^) for 2 h. BAM-SiPc content was 
determined by the method stated in Section 2.12. Human plasma L D L was a 
Calbiochem product purchased from M E R C K Biosciences, Germany. 
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2.1 5.2 Gel filtration 
A solution of human LDL (2 nmol), BAM-SiPc (0.2 nmol) or p-nicotinamide 
adenine dinucleotide (NAD+, 0.625 nmol) was chromatographed in a G-lOO 
Sephadex column (dry bead diameter = 40 - 120 |j,M; 1.8 x 21 cm) using 20 m M 
aqueous NH4HCO3 as the eluent with a flow rate of 0.5 ml per minute. After mixing 
BAM-SiPc with LDL and incubating for 90 min in dark, the mixture was also 
chromatographed in a G-lOO Sephadex column but in a smaller scale (1.8 x 9 cm). 
The presence of human LDL was determined by Bradford protein assay. BAM-SiPc 
content was monitored by fluorescence spectrometry as described in Section 2.9 and 
NAD+ content was monitored by measuring the absorbance at 260 nm. 
2.16 Statistical analysis 
Analysis of Variance (ANOVA) test was used for comparing the means 
between different treatment conditions. Statistically significant difference between 
each individual treatment group was further analyzed by the Bonferroni post hoc test. 
All the statistical comparison was accomplished by using the SPSS 14.0 for windows 
software. 
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CHAPTER 3 
Results 
3.1 In vitro photodynamic activities assay 
The in vitro photodynamic activities assay was performed to investigate the 
potency of BAM-SiPc in killing cancer cells and see whether BAM-SiPc mediated 
photodynamic activity was in a dose-dependent manner (Fig. 3.1). In the dark, there 
was no cytotoxic effect towards the cancer cells. In the presence of light, a 
dose-dependent cytotoxicity of BAM-SiPc towards different cancer cell lines could 
be observed. The cancer cells remained unaffected when treated either with 
BAM-SiPc or light alone but were effectively killed when a combined treatment was 
employed. The IC50 values of BAM-SiPc could reach nano-molar level in the 
presence of light (Table 3.1). Based on the IC50 values, it can be concluded that the 
murine macrophage J774, the colon adenocarcinoma HT29 and T84 and the 
hepatocarcinoma HepG2 have similar susceptibility towards BAM-SiPc mediated 
PDT. The hepatocarcinoma Hep3B cells was less susceptible with the IC50 of 
B AM-SiPc about two-fold higher than those of the other cancer cell lines. 
Table 3.1 IC50 values of BAM-SiPc mediated PDT towards different cancer cell 
lines 
Cultured cancer cell lines IC50 values (|LXM) 
J774 0.020* 
HT29 0.017+ 一 
T84 0.027+ 
HepG2 0.025* 一 
Hep3B 0.051^ — 
* (Lo et al., 2004.)； +(Lo et al； 2007); ^ (Lai et al, 2006) 
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Fig. 3.1 Effect of BAM-SiPc on (a) HepG2; (b) Hep3B; (c) HT29 in the presence 
(open symbols) and absence (closed symbols) of light. Cells were incubated with 
various concentrations of BAM-SiPc for 2 h, followed by illumination of halogen 
lamp with filter (cutoff wavelength \ < 610 nm, fluence rate at 24 m W c m ' , total 
fluence of 48 Jem"). Percent cell viability was determined by M T T assay. E ach 
data point represents Mean 士 S E M from three independent experiments, each 
performed in triplicate. 
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3.2 Tissue distribution of BAM-SiPc in HepG2 bearing nude mice 
Biodistribution study of BAM-SiPc was performed to investigate the retention 
time of BAM-SiPc and its tumor uptake selectivity. Result of the study was shown in 
Fig. 3.2. Maximum concentration of BAM-SiPc could be found in most of the tissues 
2 h after injection (Fig. 3.2a). In particular, the greatest retention of BAM-SiPc was 
observed in lung, and also organs of the reticulo-endotheial system namely liver and 
spleen, the amount being approximately 70%, 58% and 52% of the ID per gram of 
tissue respectively. Comparatively, liver and kidney had the fastest clearance rate of 
BAM-SiPc in which the amount of BAM-SiPc present dropped to less than 25% ID 
per gram of tissue one day after injection (Fig. 3.2a). For muscle, only a relatively 
small portion of BAM-SiPc accumulated in it. The pharmaco-kinetic profiles for skin 
and tumor, both having a higher proliferating rate, were similar to each other. Unlike 
other tissues, amount of BAM-SiPc present in skin and tumor kept increasing until 6 
hr after the injection and remained relatively constant afterwards. The maximal 
amount of BAM-SiPc accumulated in tumor was only about 2% of the ID per gram 
of tissue. 
The BAM-SiPc content in different tissues at 2 h and 1 week after injection 
were compared (Fig 3.2b). It could be observed that most of the BAM-SiPc had been 
removed from the host after 1 week. Less than 2% ID per gram of tissue of 
BAM-SiPc remained in all the examined tissues, except for kidney where 〜5o/o of 
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Fig. 3.2a. Tissue distribution of BAM-SiPc. One inmolkg"' of BAM-SiPc per body 
weight was injected intraveneously into the HepG2-bearing nude mice. At different 
time intervals, mice were sacrificed and tissues were homogenized with D M F to 
extract BAM-SiPc. Fluorescence measurement was taken to quantify the amount of 
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Fig. 3.2b Comparsion of the BAM-SiPc content in different tissues at 2 h and 1 
week after i.v. injection. Data were expressed as Mean 士 SD, n=5. 
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3.3 In vivo effect of PDT treatment with BAM-SiPc on HepG2 and 
HT29 tumor growth 
3.3,1 Anti-tumor activities of in vivo PDT with BAM-SiPc 
One jumolkg"' of BAM-SiPc was i.v. injected into the tumor-bearing nude mice 
to study the photodynamic efficacy of BAM-SiPc in an animal model. The 
anti-tumor effect of the in vivo photodynamic treatment with BAM-SiPc was shown 
in Fig. 3.3. Both HepG2 and HT29 tumor grew normally before introducing PDT 
treatment. When illumination was applied, HepG2 tumor gradually regressed at a 
constant rate while the size of the tumor and its integrity remained unchanged for the 
three control groups (BAM-SiPc control, light control and no treatment control) 
throughout the course of experiment. On Day 25 (i.e. 15 days after the application of 
PDT), the size of the tumor has regressed to only 15% of the initial tumor volume for 
the P D T treatment group. 
For HT29, growth of the tumor was significantly retarded for the first 10 days 
after BAM-SiPc mediated PDT. Thereafter, HT29 tumor resumed normal growth. 
For the three control groups, normal tumor growth could be observed. The doubling 
time for the tumor size of the control groups was about 15 days, using the days for 
the start of the measurement (Day 6) as the reference point. For the PDT-treated 
group, the tumor size only increased in 〜80o/o at the end of the experiment (Day 25). 
All the treated and control mice had normal activities and did not show any 
observable discomfort. 
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Fig. 3.3 Tumor growth curve for (a) HepG2 (n = 8) and (b) HT29 (n = 6) 
tumor-bearing nude mice treated with BAM-SiPc mediated PDT. Experiments 
were divided into four different groups, PDT- treated (•); BAM-SiPc control (x); 
Light control (•) and No treatment control (•). The dose of BAM-SiPc used was 1 
|amolkg-i while the laser fluence was at 30 Jcm"^. Data represent Mean 士 SD of the % 
tumor size. Percent tumor size referred to the relative volumes of the solid tumor 
developed on the nude mice. *, p < 0.05 (One-way A N O V A ) when compared with 
all other groups. 
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3.3.2 Dosage effect on anti-tumor activities by BAM-SiPc mediated PDT 
a. Effect of different drug dose 
The dosage effect of BAM-SiPc on PDT efficacy was shown in Fig. 3.4. 
Neither 0.5 lamolkg'' nor 0.25 |amolkg"' could produce any tumor regression or 
tumor growth retardation effect on HepG2 and HT29 solid tumor. A normal tumor 
growth curve could be observed for both groups and was similar to the light control 
(0 )j,molkg"') group (p > 0.05). BAM-SiPc injection doses higher than 1 |Limolkg"' (i.e. 
2 i^molkg-i, 4 |amolkg-i) were also studied. However, the mice suffered great 
discomfort and died within one day (data not shown). Hence, 1 jiimolkg'' of 
BAM-SiPc was the optimum dose to produce significant anti-tumor effect used in 
PDT. 
b. Effect of different light dose 
The effect of different light doses on eradicating tumor was also investigated. 
In the experiment, the dose of BAM-SiPc was fixed at 1 |Limolkg"^  When compared 
with the BAM-SiPc control group (0 Jcm"^), fluence rate at 30 Jcm'^ and 60 Jcm"^ but 
not 15 Jcm-2 could produce significant anti-tumor effect in the HepG2-bearing nude 
mice (Fig. 3.5). Mice treated with 30 Jcm"^ of light were free of any observable 
physical damage while skin burning was obvious when the light dose was increased 
to 60 Jcm-2 (Fig. 3.6). Nevertheless, the physical activity of the mice was not 
inhibited regardless of the fluence rate of light used in the experiment. 
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Fig. 3.4 Dose response curve of BAM-SiPc on (a) HepG2 and (b) HT29 tumor 
growth (n = 5). Experiments were divided into four groups, 0 ^ imolkg] (•); 0.25 
l^ molkg-i (•； 0.5 i^ molkg-i (x) and 1 |imolkg"^  (•). All animals were illuminated 
with laser wavelength 675 土 3 nm, (0.1 W , 5 min, total fluence rate ~ 30 Jcm'^) at 
24 hr post injection. Data represent Mean 士 SD. *, p < 0.05 (One-way A N O V A ) 
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Fig. 3.5 Dose response curve of the laser light source (wavelength 675 土 3 nm) 
on HepG2 tumor growth (n = 3). Experiments were divided into four groups, 0 
Jcm-2 (•); 15 Jcm-2 (•)； 30 Jcm"^ (x); 60 Jcm"^ (•)• All animals were i.v. injected 
with 1 |j.mol BAM-SiPc per kg body weight. Data points represent Means 士 SD. *, +, 
p < 0.05 (One-way A N O V A ) referred to the statistical significant difference for 30 
Jcm-2 肌d 60 Jcm-2 ^ hen compared with the dark control group. 
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國 
Fig. 3.6 Snapshots for the P D T treated mice. HepG2 bearing nude mice were 
treated with either 30 Jcm'^ (Left) or 60 Jcm'^ (Right) laser. 
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3.4 Analysis of intrinsic toxicity induced by BAM-SiPc mediated 
PDT 
3.4.1 H & E staining of liver sections of nude mice after in vivo PDT 
H & E staining of the liver sections was performed to investigate whether 
hepatic toxicity was induced by in vivo PDT treatment with BAM-SiPc. The H & E 
stained liver section excised 24 h after in vivo PDT was shown in Fig. 3.7(a). From 
the microscopic images, there was no apparent cellular damage of the liver sections 
in the P D T treated group as well as in all the three control groups. Liver sections 
were also excised on 15 days after applying photodynamic treatment. Again, there 
was no observable damage for the liver sections in all the four groups (Fig. 3.7b). 
Thus, such treatments seemed to be free from inducing both acute and chronic 
hepatic toxicity. 
3.4.2 Enzyme activities assay for the plasma of in vivo PDT treated mice 
Elevation of ALT and A S T activities will suggest the presence of liver damage 
while elevation of C K activity will suggest that significant heart damage is induced. 
The level of these enzyme activities in plasma were assayed to analyze whether there 
was any hepatic or cardiac injury induced by BAM-SiPc mediated PDT. Plasma of 
the nude mice was obtained 15 days after in vivo BAM-SiPc mediated PDT. Plasma 
enzyme activities assay showed that there was no statistically significant difference 
among the four treatment groups (Fig. 3.8, p > 0.05，One-way A N O V A analysis), 
suggesting that there was no significant chronic heart and liver damage after PDT 
with BAM-SiPc. 
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Fig. 3.7 Representative microscopic images (from three independent 
experiments) of H & E staining for liver sections of BAM-SiPc mediated PDT 
treated mice. Livers were excised from the nude mice (a) 24 hr and (b) 15 days after 
treatment. 1-4: PDT-treated; BAM-SiPc control; Light control and No treatment 
control, respectively. Left: lower magnification (lOx); Right: higher magnification 
(40x) of images enclosed in the white frame showing the region around the hepatic 
artery. 
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Fig. 3.8 Plasma enzyme activities of nude mice which has undergone various 
treatments. Plasma samples were obtained 15 days after in vivo BAM-SiPc 
mediated PDT and their ALT, AST (n = 8) and CK (n = 5 or 6) activities were 
assayed by commercial enzyme assay kits, (a) - (d): PDT-treated; BAM-SiPc control; 
Light control and No treatment control, respectively. Data represent Mean 土 SD. 
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3.5 BAM-SiPc metabolism in the in vitro culture cells and liver 
homogenate 
3.5.1 Cellular uptake ofBAM-SiPc 
The time course of the cellular uptake of BAM-SiPc was followed to 
determine the time at which the cells has attained maximal uptake of BAM-SiPc (Fig. 
3.9). There was a continuous increase in the accumulation of BAM-SiPc in HepG2 
cells for 2 h after the addition of BAM-SiPc but the rate of uptake had gradually 
decreased with time. At time = 2 h, maximal uptake has been attained. After that, the 
curve of cellular uptake reaches a plateau which indicates that the amount of 
BAM-SiPc in HepG2 cells remained relatively constant. Based on the result, it could 
be observed that around 40- 50% of the amount of BAM-SiPc initially added to the 
cell (0.05 nmol) could be retained inside the cell. 
3.5.2 BAM-SiPc metabolism in cultured normal liver cells and cancer cells 
The ability in metabolizing BAM-SiPc was compared between the liver cancer 
cells HepG2 and the normal liver cells WRL-68. As maximal uptake of BAM-SiPc 
could be achieved at time = 2 h, it was chosen as a reference point for the study of 
BAM-SiPc metabolism. In this experiment, the confluency of the cell samples had 
reached around 80% to 90%. The residual amount of BAM-SiPc present in different 
samples was shown in Fig. 3.10. The intrinsic fluorescence given by the cell lysate 
(sample a) and the culture medium (sample f) were negligible. Comparison of the 
fluorescence given by the mixture of cell lysate and BAM-SiPc (sample d) with that 
of BAM-SiPc only (sample e) showed that the fluorescence intensities were similar 
to each other. It indicates that the cell lysate would not cause any reduction in the 
fluorescence intensity. 
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Fig. 3.9 Time course of the cellular uptake for BAM-SiPc by hepatocarcinoma 
HepG2 cells. BAM-SiPc (0.5 ^ iM) was incubated with HepG2 cells (1 x 10^ ) for 
different periods of time. BAM-SiPc was extracted from the cells by DMF. Amount 
of BAM-SiPc was quantified by fluorescence measurement. Data represent mean 士 
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Fig. 3.10 Comparison of the ability of metabolizing BAM-SiPc between the 
hepatocellular carcinoma HepG2 cells (shaded) and the liver cells WRL-68 
(filled). Cells were incubated with 0.5 ^ iM BAM-SiPc for (a) 0 hr; (b) & (c) 2 h. 
After removing BAM-SiPc solution, samples were then washed with PBS. Samples 
(a) & (b) were immediately extracted with D M F while sample (c) was allowed to 
further incubate for 24 h with culture medium before D M F extraction. Sample (d) 
represents the control experiment in which 0.5 juM BAM-SiPc was incubated with 
cell lysate while sample (e) represents the sample with 0.5 ^iM BAM-SiPc only; 
Sample (f) refers to the sample of the intrinsic fluorescence given by the cell lysate 
only. Data represent Mean 土 SD，n=3. 
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At time = 2 h, there was 40% ofBAM-SiPc taken up by HepG2 cells which was 
similar to the findings in Section 3.5.1 0.2 nmol out of 0.5 nmol) while there was 
only ~ 25% ofBAM-SiPc taken up by WRL-68 cells. 
HepG2 cells and WRL-68 cells were further incubated for 24 h after the removal of 
BAM-SiPc when the maximal uptake has been attained (sample c). Result showed 
that there was a 40% reduction in fluorescence intensity comparing with the WRL-68 
cells that attained the maximal uptake of BAM-SiPc (sample b). However, 
fluorescence intensity remained relatively the same for the samples incubating with 
HepG2 cells. 
3.5.3 BAM-SiPc metabolism by mice liver homogenate 
In the experiment of BAM-SiPc metabolism by mice liver homogenate, the 
residual amount of BAM-SiPc was quantified by spectrophotometric measurement. 
When BAM-SiPc was mixed with liver homogenate, there was a time-dependent 
decrease of BAM-SiPc. After 24 h of incubation, less than 20% of BAM-SiPc 
remained in the samples (Fig. 3.11a). Heat-denatured liver homogenate was used in 
the control experiment, assuming that all the enzyme activities present in liver 
homogenate were abolished after the heat treatment. Amount of BAM-SiPc present 
in the samples remained approximately the same even after 24 h incubation with the 
denatured liver homogenate (Fig 3.11b). 
The phototoxicity of the metabolite was analyzed by in vitro photodynamic 
activities assay. In the dark, supernatant of the samples after incubating for 24 h with 
either native or denatured liver homogenate remained non-toxic (Fig. 3.12a and Fig. 
3.12b). 
In the presence of illumination, normal phototoxicity of BAM-SiPc was 
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observed for the samples incubated with denatured liver homogenate even after 24 h. 
Normal phototoxicity of BAM-SiPc for different samples was indicated by similar 
IC50 values and the dose-dependent cytotoxicity curve (Fig. 3.12c). However, there 
was a time-dependent decrease in phototoxicity of the samples which had been 
incubated with native liver homogenate. The dose-dependent cytotoxicity curve 
gradually shifted to the right with increase in the incubation time of BAM-SiPc with 
native liver homogenate. When the time of incubation was more than 18 hr, the 
phototoxicity of BAM-SiPc was completely abolished (Fig. 3.12d). 
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Fig. 3.11 Time course of the residual BAM-SiPc content after pre-incubation 
with (a) native and (b) heat-denatured liver homogenate. Residual amount of 
BAM-SiPc was determined by scanning the absorption spectrum from 600 nm to 800 
nm, reading of the absorbance peak (674nm) was taken for calculation. Data 
represent mean 士 S E M from three independent experiments. 
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Fig. 3.12 Effect of pre-incubation with liver homogenate on phototoxicity of 
BAM-SiPc. BAM-SiPc (8 |LIM) was incubated with (a) & (c) heat denatured liver 
homogenate or (b) & (d) native liver homogenate for various periods of time. 
Supernatant of the samples were subjected to in vitro photodynamic activities assay 
in the absence (a, b) and presence (c, d) of illumination as stated in Section 2.6 and 
cell viability was determined by M T T assay. Data represent Mean 士 S E M from three 
independent experiments, each performed in triplicate. 
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3.6 Death mechanism induced by BAM-SiPc mediated PDT 
3.6.1 Events related to cell death induced by in vitro BAM-SiPc mediated PDT 
The intracellular R O S production and cell cycle analysis were performed to 
study the biochemical mechanism of cell death induced by BAM-SiPc mediated PDT. 
Upon illumination, there was a dose-dependent increase in the relative R O S 
production. In particular, intracelluar R O S production increased by more than 3-, 2-
and 4-fold for HepG2，Hep3B and HT29 respectively at 0.1 ^ M BAM-SiPc (Fig. 
3.13) where the cell viability after photodynamic treatment was below 20%. On the 
contrary, no apparent increase in intracellular R O S could be observed in the absence 
of light. 
PI staining for cell cycle analysis of the PDT treated cells was performed to see 
whether cell cycle arrest was induced at 24 h after PDT with BAM-SiPc (Fig. 3.14). 
There was no obvious change in distribution of cells in cell cycle for the BAM-SiPc 
control and light control groups when compared with the untreated HepG2 cells. 
Arrest in Gq/GI phase of the cell cycle after PDT with BAM-SiPC could be observed. 
The treatment caused an accumulation of 79%, 82%, 85% cells in Gq/GI phase at 
0.005 |LIM, 0.01 \xM, 0.02 |LIM BAM-SiPc, a slight increase when compared with the 
77% for the solvent control. The increase in Gq/GI cell population was accompanied 
with a decrease in cell number in S-phase. When a BAM-SiPc concentration greater 
than 0.02 f.iM was used, the cell cycle distribution continued to shift from Gq/GI 
peak to the region "Debris" with increasing concentration of BAM-SiPc. At 0.1 |aM 
of BAM-SiPc, almost the entire (98%) cell population had fell into the "Debris" 
region. The "Debris" region represents the necrotic cells or those cells with 
fragmented D N A or D N A strands break. In other words, cells treated with 0.02 j^M 
BAM-SiPc had immediately undergone necrosis or apoptosis. 
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Fig. 3.13 Intracellular ROS production after in vitro PDT with BAM-SiPc. (a) 
HepG2; (b) Hep3B and (c) HT29 were treated with BAM-SiPc in the presence (open 
symbols) or absence (closed symbols) of light. After removal of BAM-SiPc, samples 
were incubated with 100 ^iM of D C F D A solution. Fluorescence intensity of the 
samples was measured with excitation at 485 nm, emission at 535 nm. Each data 
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Fig. 3.14 Cell cycle patterns of BAM-SiPc mediated PDT treated HepG2 cells. 
HepG2 cells underwent in vitro PDT with the indicated BAM-SiPc concentrations (b 
to i). (J) represents the HepG2 cells incubated with 0.1 )liM BAM-SiPc but without 
light treatment. Samples were then stained with PI solution (20 |ag/ml) for 15-30 min. 
Fluorescence from individual cells was recorded by a FASCanto flow cytometer with 
PE-A (ex 488nm; em 585nm). "Dip" referred to diploid. 
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Table 3.2 Distribution (%) of HepG2 population in different stages of cell cycle 
after PDT treatment with various concentrations of BAM-SiPc. 
Treatment G1 S G2 D e t e 
Untreated cells 74.90 13.79 8.40 
Solvent control 77.18 13.61 7.44 L ^ 
0.005 i^M n m 6.51 ^ 
0.01 |LIM 82.40 5.70 m 
0.02 laM IJ^ 5.40 
0.03 ixM ^ 7.41 
0.04 |iM 29.82 ^ 6.42 
0.05 n M ^ 4.27 7 5 ^ 
0.1 ^iM I M 0.19 9 m 
D ^ 77.18 ^ 6.99 m 
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3.6.2 Death mechanism exerted by in vivo BAM-SiPc mediated PDT 
T U N E L and H & E staining of HepG2 tumors were performed to investigate 
the death mechanism induced by in vivo BAM-SiPc mediated PDT. HepG2 tumors 
were excised at 24 h after different treatments and their histological sections were 
taken for T U N E L staining. A large population of TUNEL-positive nuclei was 
detected for the P D T treated tumors (Fig. 3.15a). It indicated that BAM-SiPc 
mediated P D T could induce D N A fragmentation in HepG2 tumor. However, when 
HepG2 tumors were either treated with BAM-SiPc or light alone, very little or 
negligible fluorescence signal could be observed, similar to HepG2 tumors with no 
treatment (Fig. 3.15 b-d). Nuclear fragmentation is one of the hallmark features in 
apoptosis. The fragmented nuclei are enclosed in nuclear envelope and form 
apoptotic bodies with other organelles. The microscope images of the H & E staining 
of the HepG2 tumors were shown in Fig. 3.16. Nuclear fragmentation was detected 
in the solid tumors excised 15 days after in vivo PDT with BAM-SiPc. This confirms 
the induction of apoptosis by BAM-SiPc mediated PDT. For the three control groups, 
the majority of the cancer cells in the solid tumor maintained their spherical intact 
nuclei. It means that HepG2 tumor grew normally and was not affected by treatments 
either with BAM-SiPc or light alone. 
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Fig. 3.15 Representative microscopic images (from three independent 
experiments) of TUNEL staining for solid tumor of BAM-SiPc mediated PDT 
treated mice. HepG2 solid tumors were excised from the nude mice 24 h after 
BAM-SiPc mediated PDT and their histological sections were stained by the T U N E L 
reaction mixture for 1 h. (a) - (d): PDT-treated tumor; BAM-SiPc control; Light 
control and No treatment control respectively. Left: lower magnification (20x); Right: 






Fig. 3.16 Representative microscopic images (from three independent 
experiments) of H & E staining for solid tumor of BAM-SiPc mediated PDT 
treated mice. HepG2 solid tumors were excised from the nude mice 15 days after 
treatment. Nuclei of the tumors were stained by Mayer's haematoxylin solution 
(purple) for 2 min and the cytoplasm was counterstained by eosin solution (pink) for 
5 min. (a) - (d): PDT-treated tumor; BAM-SiPc control; Light control and No 
treatment control, respectively. Left: lower magnification (lOx); Right: higher 
magnification (40x) of images enclosed in the white frame. 
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3.7 Effect on phototoxicity of BAM-SiPc in the presence of LDL 
3,7,1 Effect on phototoxicity ofBAM-SiPc after mixing BAM-SiPc with LDL 
HepG2 was used as a model to study the phototoxicity of the mixture of 
BAM-SiPc and LDL. In the dark, no cytotoxic effect was exerted even in the 
presence of the highest concentration of BAM-SiPc and LDL (Fig. 3.17). Thus, 
viability of HepG2 cells was not affected by adding LDL to the samples. When 
illumination was employed, normal phototoxicity was exerted against HepG2 cells in 
the absence of L D L with BAM-SiPc concentration fixed at I C 5 0 , i.e. 0.025 [iM. The 
phototoxicity of BAM-SiPc decreased with increasing amount of LDL added into the 
samples. Cytotoxic effect could not be observed when a 1:40 molar ratio of 
BAM-SiPc to L D L was used for incubating with HepG2 cells 
3.7.2 Gel filtration for analysis of the LDL-BAM-SiPc mixture 
Gel filtration chromatography was performed to determine whether LDL 
conjugated BAM-SiPc was formed after mixing BAM-SiPc with LDL. The gel 
filtration elution profiles for (a) mixture of BAM-SiPc and LDL in a small scale 
column and the elution profile of (b) NAD+，(c) BAM-SiPc, and (d) LDL in larger 
column were shown in Fig. 3.19. When the mixture of BAM-SiPc and LDL was 
chromatographed on a gel filtration column, peaks representing BAM-SiPc and LDL 
overlapped with each other. One explanation was that all the BAM-SiPc was 
conjugated with LDL. Using a larger column, it could be observed that the elution 
profiles of both L D L and BAM-SiPc showed peaks at the same elution volume (16 
ml). This was unexpected as LDL is a large molecule with a molecular weight 2.25 x 
106 whereas BAM-SiPc is a small molecule of 717.89 dalton. NAD+ (molecular 
weight 685.4) was used as a reference to estimate the retention time for the small 
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molecules. The elution profile for NAD+ showed a peak at a much larger elution 
volume of 35 ml. Based on the results, it could be concluded that the resolution of 
the gel filtration column used in this experiment was able to retain small molecule 
for a longer time and separated them from large molecule (e.g. LDL). Surprisingly, 
L D L and BAM-SiPc could not be resolved by using this gel filtration column. 
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Fig. 3.17 Effect on phototoxicity of BAM-SiPc in the presence of LDL. 
BAM-SiPc was incubated with human LDL at different molar ratio for 90 min in 
dark. Then, the phototoxicities of the samples were analyzed by in vitro 
photodynamic activities assay. Two different BAM-SiPc concentrations, one at IC50 
i.e. 0.01 I^M (shaded) and the other at 0.025 |LIM (filled), were used to incubate with 
various amount of L D L in this experiment. BAM-SiPc control and LDL control 
referred to samples of 0.025/0.01 jiM BAM-SiPc and amount of LDL used in the 
40:1 sample respectively, (a) & (b) represent the samples treated in the absence or 
presence of light respectively. Data express as mean 士 S E M from three independent 
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Fig. 3.18 Elution profiles for (a) mixture of BAM-SiPc and LDL (molar ratio of 
BAM-SiPc to LDL is 1:10) (b) NAD+ (0.625 nmol) (c) BAM-SiPc (0.2 nmol) (d) 
LDL (2 nmol). Mixture of BAM-SiPc and LDL was chromatographed on a smaller 
(1.8 X 9 cm) G-lOO Sephadex column (molecular exclusion limit: 150 kDa) while the 
other Samples were chromatographed on a larger (1.8 x 21 cm) G-lOO Sephadex 
column. In both situations, 2 0 m M aqueous NH4HCO3 was used as eluent. Elution of 
LDL, BAM-SiPc and NAD+ were monitored by the methods described in Section 
2.16. 
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CHAPTER 4 
Discussion 
Since the unendurable side effects of using Photofrin® in cancer treatment 
have been reported, Pc was thought to be a potential replacement in the application 
of cancer treatment. While metal chelation to the central core of Pc was found to be 
effective in enhancing the photodynamic activities，?，Pc 4 was one of the most potent 
PS in killing cancer cells. In recent years, researchers have synthesized many 
different kinds of phthalocyanine derivatives in an attempt to further enhance the 
P D T efficacy of the phthalocyanine based PS. BAM-SiPc is a novel second 
generation phthalocyanine-based PS. Investigation on its photodynamic activities 
was carried out to test the potential use of BAM-SiPc for clinical application. 
4.1 Anti-cancer effect of BAM-SiPc on different cancer cell lines 
Long wavelength absorption maximum (> 670 nm), efficiency in producing 
singlet oxygen are the two major prerequisites for an ideal PS. In previous study, it 
has been shown that BAM-SiPc possesses these two properties and is not altered by 
the presence of the axial substitiuents (wavelength absorption maximum: 674 nm; 
singlet oxygen quantum yield,小么：0.26)47. In terms of anti-cancer activities, B A M -
SiPc exhibited potent phototoxicity on a variety of cancer cells including human 
hepatocarcinoma HepG2 and Hep3B, human colon adenocarcinoma HT29 and T84 
and mouse macrophage 1774"^ ^ which has cancer-like properties. When the 
phototoxicity is compared, BAM-SiPc is superior to some of the well-known PS like 
A L A and Photofrin®. For example, the ICgo (i.e. the concentration of drug that results 
in 20% cell viability) of A L A and Photofrin® against HepG2 were 50 |j.gmr' and 5 
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^gml"', i.e. about 0.3 m M and 4.41 |LIM respectively (light fluence was fixed at 25 
Jcm-2)53. For BAM-SiPc，the ICgo against HepG2 was 0.04 |aM (light fluence was 
fixed at 24 Jcm"^) which was > 7000-fold and > 100-fold more potent than A L A and 
Photofrin® respectively. In addition, dark toxicity was exerted by A L A and 
Photofrin® when concentrations greater than ICgo were used but BAM-SiPc exhibited 
no dark toxicity as shown by the result of in vitro photodynamic activities assay. As 
BAM-SiPc exerts potent anti-cancer activities on a broad spectrum of cancer cell 
lines, it is a good candidate for testing in in vivo experiments. 
4.2 Tissue distribution of BAM-SiPc in HepG2 bearing nude mice 
Biodistribution study of BAM-SiPc was performed to evaluate the tumor 
selectivity and the retention time of the compound inside the host. It was believed 
that porphyrin with greater hydrophobicity could bind to the tumor tissue with higher 
affmity54-56 Thus, increasing the hydrophobicity of a PS will enhance its tumor 
selectivity. However, the steric factor of the compound should also be considered 
because the photodynamic efficacy of a PS will drop if there is a large bulky side 
chain which will hinder the uptake by tumor tissue^ .^ On the other hand, some 
researchers had tried to test the potential use of a hydrophilic PS because 
hydrophobic compounds tend to have higher degree of aggregation which will 
decrease the phototoxicity of the compound. Although increasing the hydrophilicity 
of a PS can reduce the aggregation"^ '^^ ,^ it should be noted that hydrophilic PS will 
clear faster from the host and hence the accumulation by malignant tissue will 
decrease. Therefore, an ideal PS should have a balanced degree of hydrophobicity 
and hydrophilicity to compromise the problem of tumor selectivity, aggregation of 
the compound and the retention of PS in the host so that it could maximize the 
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phototoxicity to the malignant tissue but will not cause skin photosensitivity due to 
prolonged retention of PS. 
The result of the biodistribution study, showed that BAM-SiPc has a high 
affinity to the lung and the reticulo-endothelial systems (Fig. 3.2a). It has long been 
suggested that PS were preferentially accumulated by reticulo-endotheial cells^ .^ m-
T H P C and mTPP(glu)3 are some examples which has been reported in some recent 
studies59’60-6i. Brasseur et al claimed that persistent retention of PS by the liver (73% 
ALClPc ID per gram of tissue for 1 week) could result in hepatic toxicity^ .^ Although 
BAM-SiPc has preferential uptake in liver, a significant amount of BAM-SiPc could 
be removed from the liver within 24 h (Fig. 3.2a). It was almost completely cleared 
after 1 week (Fig. 3.2b). In view of such pharmacokinetic properties, hepatic toxicity 
due to BAM-SiPc was unlikely. However, it should be noted that such speculation 
should be accompanied by some intrinsic toxicity analyses which will be discussed 
in Section 4.5. 
For the tumor, maximum accumulation of BAM-SiPc was found at 6 h after i.v. 
injection. The amount of BAM-SiPc accumulated in the HepG2 tumor was persistent 
even for 24 hr post-injection. At the same time, BAM-SiPc concentration in other 
organs/tissues dropped significantly except for skin. Since the tumor to tissue BAM-
SiPc concentration ratio was better than that at 2 h post-injection, illumination was 
employed at this time. BAM-SiPc is an amphiphilic PS. At the beginning, it was 
expected that BAM-SiPc might have good selectivity in tumor uptake and exhibit 
high photoxicity towards the solid tumor. Although BAM-SiPc could persistently 
accumulate in HepG2 tumor, the uptake of BAM-SiPc by HepG2 tumor was 
relatively low (Fig. 3.2a). Such phenomenon may be accounted for by the elevated 
and rapid PS retention by the reticulo-endothelial system^^. Regarding to the issue of 
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selective accumulation of PS in tumor, there were reports emphasizing that some PS 
could show an impressive tumor to organ/tissue uptake ratio. Chin et al. ^^ has found 
that the ratio of Hypocrellin B (a PS) in M G H human bladder tumor versus muscle 
could be as high as 2.81 but the accumulation of Hypocrellin B in tumor was still 
lower than other organs/tissues such as liver, spleen and skin. In the study conducted 
by Masumoto et al amount of ATX-SlONa(II) (a PS) in Colon 26 carcinoma 
sustained the highest concentration at any time following ATX-S1 ONa(II) 
administration when compared with other organs/tissues. Brasseur et al.位 used 
AlPc-PVA, an AlPc derivative, as a PDT agent in their study. They found that the 
tumor uptake of of AlPc-PVA could be as high as 15% ID per gram of tissue. 
Comparing to those findings, it was disappointed to observe that BAM-SiPc showed 
a relatively low tumor uptake 2%) and low tumor to organ/tissue BAM-SiPc 
concentration ratio (< 1). This may render its clinical application inefficient^ .^ 
Despite this disappointing finding, the amount of BAM-SiPc present in the tumor 
tissue could still be significant enough (> 2 nmol per gram of tissue) to exert 
phototoxicity to malignant tissue and cause tumor cell, death. 
Skin photosensitivity can still be induced for up to weeks or months after 
administration of the commercially available PS，’ 66-67. Comparatively, BAM-SiPc is 
a better PS because the rate of clearance of BAM-SiPc was much faster according to 
the result of biodistribution study. This will bring much convenience to the patient 
because patients' normal activities can resume a week after BAM-SiPc 
administration with a low risk of developing skin photosensitivity. 
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4.3 In vivo effect of BAM-SiPc mediated PDT on HepG2 and HT29 
tumor growth 
There are reports stating the successful application of PDT on eradicating or 
controlling the tumor growth in animal models. Whitacre et al. 20 found that Pc 4 
mediated PDT could inhibit the growth of SW480 human colon cancer xenografts in 
athymic mice. Brasseur et al 说 also reported that a significant growth delay of colon 
adenocarcinoma Colo-26 tumor could be observed after treating the tumor-bearing 
mice with PDT using AlPc or its derivatives. The anti-tumor efficacy of BAM-SiPc 
mediated PDT was evaluated by following the tumor growth for 15 days post-
treatment. When HepG2 tumor was treated with BAM-SiPc or laser alone, HepG2 
tumor remained unaffected, similar to the "no treatment" control group. A significant 
tumor regression was observed for the HepG2 tumor PDT treated with BAM-SiPc. 
The trend and the level of tumor regression (> 80%) may indicate that a complete 
eradication of HepG2 could be achieved by the dosage of drug and light used in this 
study (1 i^ molkg-i of BAM-SiPc, total fluence 30 Jcm"^ ). Thus, BAM-SiPc or laser 
alone will not exert any cytotoxicity to the tumor cells but a lethal cytotoxicity will 
be produced when there is a combination of drug administration and illumination on 
target tissue. 
Study about the effect of PDT on the growth of HT29 tumor was conducted in 
the past by some researchers. Hajri et al. ^^ showed that a significant tumor growth 
delay for 3 week could be produced when the HT29 tumor-bearing athymic nude 
mice were photodynamically treated with Photofrin® and Pheophorbide a (30mgkg"' 
i.e. 26 i^ molkg-i and 50 |Limolkg'^  of body weight for Photofrin® and Pheophorbide a 
respectively with the laser fluence at 100 Jcm'^). Bourre et al ^^ also demonstrated 
that growth of HT29 tumor could be significantly delayed by PDT with the use of 
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diphenylchlorin PS (5 mgkg"' of body weight, i.e. 10 ^ imolkg'' of body weight with 
laser fluence at 300 Jcm"^). In our study, in vivo BAM-SiPc mediated PDT was also 
found to be effective in controlling the growth of HT29 tumor. There was a 
significant growth retardation of HT29 tumors for 10 days post-treatment for the 
P D T treated group while tumors for the three control groups remained unaffected 
and grew normally. In terms of dosage of the treatment, BAM-SiPc is better than 
Photofrin®, Pheophorbide a and diphenylchlorin PS because similar anti-tumor effect 
could be produced by PDT with BAM-SiPc at a lower drug dose and laser fluence. 
In cancer treatment, chemotherapeutic drug can be divided into two classes, 
cytotoxic and cytostatic. Cytotoxic drugs are drugs that can directly kill the cancer 
cells while cytostatic drugs are those that can stop the cell from multiplying instead 
of inducing the cell death. Undoubtedly, BAM-SiPc mediated PDT exerted cytotoxic 
effect to HepG2 tumor as shown by the significant tumor regression. For HT29, 
BAM-SiPc mediated PDT seemed to display cytostatic effect because of the presence 
of tumor growth delay. However, it is more likely that growth retardation instead of 
regression may be due to a balance between the number of tumor cells died and the 
number of newly proliferated cells because of the instant cytotoxic effect exerted by 
R O S produced in PDT^' ^  For those tumor cells unaffected by BAM-SiPc mediated 
P D T treatment, they continued to proliferate and the size of the tumor increased 
again at 10 days after the treatment. Some tumor cells were unaffected by the 
treatment. This may be due to the fact that they are located deeply inside the tumor 
where the laser could not reach to activate BAM-SiPc. It might also be possible that 
those cells were resistant to PDT treatment. However, reports of PDT-resistant cells 
were only based on some in vitro studies^ '^^ ®. Comparing the response for the 
treatment by HepG2 and HT29 tumors, BAM-SiPc mediated PDT appeared to be 
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more effective against HepG2 tumor than HT29 tumor. It could be due to the reason 
that HepG2 tumor was more efficient in accumulating BAM-SiPc. However, further 
investigation is necessary to understand why there is difference in the response in 
these two tumor models. Nevertheless, based on the result of in vivo PDT, it is well-
demonstrated that BAM-SiPc mediated PDT is effective in controlling the 
progression of tumor in in vivo systems. 
The dosage effect of BAM-SiPc and light was also investigated in this study. 
For the three doses of BAM-SiPc (1 j^ molkg'', 0.5 |amolkg"', 0.25 )Limolkg"') was 
chosen in the experiments, only 1 ^ molkg'' could produce significant anti-tumor 
effect on both HepG2 and HT29 tumor. For the light dose experiment, anti-tumor 
effect was not obvious at 15 Jcm'^. The laser energy transmitted to the tumor was 
inadequate and thus the cytotoxicity produced could be tolerated by the tumor cells 
and hence they survived. Although both 30 Jcm"^ and 60 Jcm'^ could exhibit 
significant anti-tumor effect, a burning scar was observed at the site of illumination a 
day after the treatment when the highest dose in this experiment was used. As there 
was no dramatic increase in temperature around the site of illumination, the 
formation of burning scar was likely to be due to photo sensitization of the skin by 
laser with high fluence. Such dose appeared to be too drastic to the host and also the 
cosmetic effect was unfavourable that would take a very long time to heal. Thus, it 
was unsuitable to use in P D T treatment. The only optimum drug and light dose used 
in P D T with BAM-SiPc were thus 1 |Limolkg"' and 30 Jcm'^. 
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4.4 Analysis of the safety of using BAM-SiPc as a potential agent in 
PDT 
Haematoxylin is a base that will preferentially bind to the acidic components 
of the cell. Nucleic acids are the highly acidic components found in the nucleus. 
Thus, nucleus of the cells can be stained by haematoxylin and a dark purple colour 
will be given. On the contrary, eosin is an acid that will preferentially bind to the 
basic components of the cell. Many cytoplasmic constituents are basic in nature. 
Thus, cytoplasm can be stained by eosin in which a pinkish colour will be given. 
Haematoxylin staining can help identify the integrity of the nuclei structure while 
eosin serves as a counter stain to enhance the contrast of the nuclei staining. Thus, H 
& E staining of liver sections will allow us to investigate whether hepatic injury has 
been induced”. 
Since liver is the organ which accommodates the largest amount of BAM-SiPc, 
it was chosen for the analysis of the intrinsic toxicity induced by BAM-SiPc. 
Sinusoidal congestion, cytoplasmic vacuolization, hepatocellular necrosis and 
neutrophil infiltration are some general features of hepatic damage?�. It has been 
reported that hepatic injury would be resulted with high dosage treatment of 
ZnPcP2S2 on Wistar rat?〗. Hepatic injury on Syrian golden hamster was also found 
when treated with veteporfrin combined with high light dose^ "^ . From the microscopic 
images of the liver sections, general features for hepatic injury, for example, 
hepatocellular necrosis, was not apparent for the mice treated with BAM-SiPc or 
light alone. Similarly, the integrity of the hepatocytes around the region of hepatic 
artery and its nuclear structure has preserved (Fig. 3.7) for the PDT-treated mice. 
Also, no significant neutrophil infiltration could be observed for the examined liver 
sections. 
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The level of plasma enzyme activities was also utilized as a marker for testing 
intrinsic toxicity has been induced. As most enzymes are predominantly present 
inside the cells but not in plasma, the level of plasma enzyme activities was often 
used as a marker for tracing any organ/tissue damage. A L T and AST are abundant in 
liver and heart while C K is abundant in cardiac muscle. Thus, ALT，AST and C K 
were used in this study to analyze whether there was hepatic or cardiac injury^ ^ 
According to the result of enzyme activities assay, treatment with BAM-SiPc or light 
alone as well as the combined treatment did not induce any hepatic or cardiac injury. 
Thus, the present protocol of BAM-mediated PDT treatment did not induce any 
apparent intrinsic toxicity to the host. 
Although toxicological analysis has only been done on heart and liver, it is 
believed that intrinsic toxicity on organs like spleen and kidney was unlikely because 
the amount of BAM-SiPc accumulated in these organs was lower compared with that 
in the liver. Thus, significant organ/tissue damage was not likely to be suffered 
when BAM-SiPc mediated PDT was used in anti-cancer treatment. 
4.5 Metabolism of BAM-SiPc 
It was found that the rate of uptake of BAM-SiPc gradually decreased with 
time. Maximal uptake and equilibrium could be achieved at 2 h after adding BAM-
SiPc to HepG2 cells (Fig. 3.7). Based on the result, it was expected that the highest 
photototoxicity can be produced by incubating the cancer cells with BAM-SiPc for 
2 h. The 2 h time point was also selected as the reference time point for the study of 
BAM-SiPc metabolism because it provided greatest sensitivity for the experiment. 
In our study, the ability of metabolizing BAM-SiPc was compared between the 
cancer cells HepG2 and the liver cells WRL-68. It was found that the BAM-SiPc 
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inside HepG2 cells was not metabolized as indicated by the unchanged fluorescence 
intensity after 24 h of incubation. The result of incubating BAM-SiPc with the cell 
lysate was a control used to indicate that any reduction of fluorescence intensity of 
the sample was not due to chemicaJ reaction or conjugation of BAM-SiPc with 
intracellular component. The inability in metabolizing BAM-SiPc can provide an 
explanation for the persistent retention of BAM-SiPc inside the HepG2 solid tumor. 
Hajri et al. 65 suggested that the amount of PS uptake and PS retention would be very 
different depending on different kinds of PS and tumoral models. In their study, they 
found that Photofrin® could retain longer inside the cells than pheophorbide a. For 
pheophorbide a, its concentration in colon cancer cell HT29 were still 3-fold higher 
than rat intestine cell IEC17 3 days after addition of PS. So, the result of the present 
study somehow agrees with their findings. In our study, there was reduction in 
fluorescence intensity when the liver cells WRL-68 taken with BAM-SiPc was 
further incubated for 24 h. It indicated that BAM-SiPc could be degraded by 
enzyme-catalyzed reaction or excreted outside from the intracellular compartments. 
The residual amount of BAM-SiPc and metabolite obtained by organic extraction 
was too minute for stud ying its in vitro photodynamic activity. So, there is no 
information about whether the metabolite is photoactive or not in this experiment. 
One of the possibilities for the difference in metabolizing BAM-SiPc between 
HepG2 and WRL-68 cells might be that the abnormal intracellular environment of 
HepG2 cells provides an energy favourable environment for holding BAM-SiPc". 
The other possibility is that enzymes responsible for metabolizing BAM-SiPc were 
defective or down-regulated in the cancer cells. BAM-SiPc was unable to be 
metabolized by HepG2 cells. This can also explain why the PS tends to selectively 
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accumulate in malignant tissues and persist longer than the normal tissue 
counterparts. 
Studies of drug metabolism are often conducted to evaluate the efficiency for 
the drug clearance and also whether the drug has been detoxified or a toxic active 
metabolite has been produced. Drug metabolism often involves biochemical 
modification or degradation by a series of enzyme-catalyzed reactions. It includes 
two phases, Phase I and Phase II. Phase I drug metabolism involves chemical 
reactions such as oxidation, reduction, hydrolysis and cyclization, etc. These 
reactions are catalyzed by several enzyme systems, mainly the Cytochrome P450 
enzyme system. Phase II drug metabolism mainly involves conjugation reactions 
such as conjugation with glucuronic acid, sulfonates, etc. When the metabolite of the 
drug after the Phase I reaction is not polar enough for excretion, Phase II reactions 
will then be carried out to conjugate the drug with a more polar molecule. Metabolite 
after Phase II reaction will then be readily excreted^ .^ 
Investigation on the metabolism of PS has been conducted for many years. 
Reports about the metabolism of Photofrin could be traced back to more than a 
decade ago. Bellnier et al. ” found that Photofrin II was very difficult to be 
metabolized in vivo using DBA/2 Ha-DD mice as the animal model. They also 
suggested that Photofrin II was primarily excreted through the bile gut pathway. 
Whelpton et al. ^ ^ suggested that 5, 10，15，20-tetra [m-hydroxyphenyl] chlorine (m-
THPC) could be photochemically oxidized to a polar, hydroxylated derivative and 
could be detected in the faeces. However, it was later found to be an artifact 
generated during sample administration, collection, preparation and extraction. They 
have reported that m-THPC was actually unable to be metabolized and no 
metabolites could be detected by means of HPLC-electrospray mass spectrometry^^. 
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Desroches et al ,59 and Bellnier et al. both have similar claims in their recent 
studies. For example, Descroches et al ^^ has found that m-THPC derivatives were 
unable to be metabolized in mice while Bellnier et al. suggested that no metabolite 
could be detected in the patient infused with pyropheophorbide-a derivatives or by 
incubating such derivatives with pooled human microsomes. 
In the present study, BAM-SiPc was incubated with mice liver homogenate for 
the investigation of metabolism of BAM-SiPc. Mice liver homogenate was chosen to 
mimic the actual situation of the BAM-SiPc metabolism inside the liver. According 
to the result, BAM-SiPc content decreased with increasing time of incubation. It 
indicated that BAM-SiPc was metabolized by the native liver homogenate in a time-
dependent manner. BAM-SiPc content remained constant when the liver homogenate 
was first subjected to heat denaturation. It suggested that the reduction in BAM-SiPc 
content was due to enzyme-catalyzed degradation as all the enzyme activities should 
be virtually abolished after the heat treatment. 
In contrast to many previous reports, BAM-SiPc was found to be metabolized 
by cultured normal liver cells and mice liver homogenate. However, the metabolite 
of BAM-SiPc could still be toxic to the host. Also, skin photosensitivity will still be 
suffered by the patient if the metabolite is photoactive. Laville et al proposed 
that some PS derivatives could be metabolized by in vitro cultured cancer cells and 
also in an in vivo situation. They found that the glycosidic bonds of glycoconjugated 
porphyrins or chlorine6 could be cleaved by endogenous glycosidases present inside 
the cancer cells, thus releasing the free porphyrin or chlorin. In that case, 
phototoxicity could still be induced though the biochemical properties of the PS such 
as subcellular localization and rate of clearance would be altered. In the present 
investigation, the metabolite of BAM-SiPc after incubating with liver homogenate 
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was recovered by organic extraction. It was analyzed by the in vitro photodynamic 
activities assay. It was found that the metabolite was non-toxic both in the dark and 
in the presence of illumination. Since a non-discriminative extraction method was 
employed in this study, many difficulties have to be overcome (e.g. the purity of the 
target compound). At the moment, the metabolite has not been identified. It was not 
known whether detoxification of BAM-SiPc was by the chemical modification in 
Phase I reaction or by the conjugation of polar molecules which inactivates the 
photosensitizing property of BAM-SiPc in Phase II reaction. In the future, liquid 
chromatography and MALDI-TOF mass spectrometry can be used to trace the 
identity of the metabolite and that will enable us to understand the detail for the 
metabolism of BAM-SiPc in liver^ '^ Nevertheless, combining this finding with 
the result of the biodistribution study, it is expected that the risk of suffering any 
adverse side effect is low for the patients administered with BAM-SiPc in PDT. 
4.6 Mechanism of the apoptosis triggered by BAM-SiPc mediated 
PDT 
P D T can induce cell death either by apoptosis or necrosis depending on factors 
such as the dose of drug and light used in the treatment^ '^^ '^ . While singlet oxygen is 
widely accepted as the major cytotoxic agent produced in PDT, the subsequent 
generation of R O S such as hydroperoxide, superoxide anion and oxygen free radicals 
can also play a crucial role in inducing cell death:’ In the present study, the 
D C F D A assay was employed to determine the intracellular R O S production by 
BAM-SiPc mediated PDT. D C F D A can only be deacetylated by intracellular esterase 
to 2,，7’-dichlorofluorescein (DCF). It is known that DCF does not detect singlet 
oxygen but rather react with hydroperoxides to give the characteristic fluorescence. 
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Thus，ROS which has been measured in this study reflected the formation of ROS 
species by the reaction of singlet oxygen formed earlier after PDT with other 
molecules^®' ^ ^ 
Many studies have reported the role of R O S in inducing cell death. For 
example, the R O S overproduction induced by p53 over-expression can trigger the 
downstream pathway of mitochondria-mediated apoptosis^ '^ In PDT, the sudden 
increase in intracellular oxidative stress leads to the oxidation of cellular proteins. 
These oxidized cellular proteins serve as a death signal to trigger a series of pro-
apoptotic events. Lam et al, ^^ used Pc 4 mediated PDT to trigger apoptosis in the 
epidermoid carcinoma cells A431. They found that the mitochondrial ROS produced 
subsequent to P D T treatment would induce mitochondrial inner membrane 
permeabilization and lead to cell death after a series of downstream events. In the 
present study, BAM-SiPc mediated PDT could immediately increase the intracellular 
R O S production in the cancer cell lines (HepG2, Hep3B and HT29). The dose-
dependent curves for the survival of the tested cancer cell lines correlated well with 
R O S production. When comparing the ROS production for each cancer cells with its 
I C 5 0 values of BAM-SiPc, the results were correlated as well. As stated in Section 
3.1, the susceptibility of the cancer cells used in this study is in the following order: 
HT29 > HepG2 > Hep3B which followed the same order for the intracellular ROS 
production (HT29, > 4-fold; HepG2, > 3-fold; Hep3B, > 2-fold). The difference in 
the susceptibility to BAM-SiPc mediated PDT for each cancer cell line might be due 
to their difference in the resistance to oxidative damage. Such phenomenon 
correlates with the ability of the cell to cope with intracellular oxidative stress, in 
other words, the efficiency of the cells to scavenge intracellular ROS by the anti-
oxidation machinery. Magi et al. ^^ suggested that the reduced glutathione (GSH) 
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content is one of the factors which is important for scavenging the ROS produced 
after PDT. It could also be one of the reasons why there was difference in the 
susceptibility of the cancer cells towards BAM-SiPc mediated PDT. A more detailed 
study on screening the potential cellular proteins targeted by BAM-SiPc mediated 
PDT could be performed to elucidate the signaling events involved in PDT-mediated 
apoptosis. In some recent studies, several proteins have been identified as the 
potential target, for example tubulin, p-actin, HSP (heat shock protein) 60, HSP 70， 
etc. Extensive carbonylation is often found in these proteins after PDT^^' 89. 
Some researchers had proposed that apoptosis induced by PDT was a result of 
cell cycle arrest. Ahmad et al.卯 had utilized Pc 4 mediated PDT on A431 cells to 
study the mechanism of PDT induced cell death. They discovered that there was a 
significant cell cycle arrest in Gq/G i phase and concomitant decrease of cell number 
in the S-phase. In the same study, they suggested that the occurrence of cell cycle 
arrest was due to the upregulation of a cyclin kinase inhibitor, namely 
WAFl/CIPl/p21 which is the key-regulator of Gi checkpoint to S-phase. Down-
regulation of Gi-phase cyclins, cyclin D, cyclin E, cdk2 (cyclin dependent kinase 2) 
and cdk6 were observed and accompanied by the upregulation of WAFl/CIPl/p21. 
Cell cycle arrest was finally induced. In a later study, Ahmad et al have also found 
the involvement of Retinoblastoma (pRb) and E2F family transcription factors (E2F), 
DP 1 and DP2 in Pc 4 mediated cell cycle arrest. Combining with the evidence of the 
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involvement of increased production of nitric oxide species (NO) , they have 
proposed a model for the Pc 4 mediated cell cycle arrest (Fig. 4.1). Haywood-Small 
et al. 93 had also found that cell cycle arrest in Gq/G i phase was also induced when 
human cervical carcinoma cells SiHa were treated with ZnPc derivatives mediated 
PDT. In consensus to the findings of Ahmad et al. and Haywood-Small et al. 
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cell cycle arrest in GQ/GI phase could be detected when HepG2 cells were PDT 
treated with BAM-SiPc at concentration lower than 0.02 |LIM. Although the 
magnitude of the cell cycle arrest of HepG2 cells found in this study (8% compared 
with solvent control group) was less than that of the Pc 4 — PDT treated A431 cells 
(> 25% compared with the control), it was convincing to believe that apoptosis 
triggered by BAM-SiPc mediated PDT was a result of cell cycle arrest. When a 
BAM-SiPc concentration greater than 0.02 fiM was used, significant amount of 
necrotic or apoptotic cells could be observed one day after PDT treatment. It could 
be due to the drastic increase in oxidative stress that resulted in extensive protein 
oxidation. Those oxidized proteins would immediately trigger the apoptotic response. 
Another possible reason is that ROS floods inside the cells which cause serious and 
irreversible damage to cell, leading to necrosis. However, such speculation is quite 
preliminary. It should also be noted that unsynchronized cells were used in this 
experiment. Experiment should be repeated in order to confirm such speculation and 
Western blot analysis on cell cycle related proteins should be done to elucidate the 
intracellular signaling events involved in BAM-SiPc photodynamic therapy mediated 
apoptosis. 
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Fig. 4.1 Schematic diagram for proposed model of Pc 4 mediated PDT cell cycle 
arrest. (Ahmad et al” 1999) 
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4.7 Death mechanism induced by in vivo PDT with BAM-SiPc 
There are two major pathways for triggering apoptosis: the extrinsic pathway, 
i.e. the death receptor ligand binding induced apoptosis and the intrinsic pathway 
which is also called mitochondria-mediated apoptosis. Extrinsic pathway or death 
receptor-ligand binding pathway, as the name implies, involves the binding of a 
death receptor ligand (e.g. Fas ligand) with the death receptor (e.g. Fas-APO-1 
receptor) and forms the death inducing signaling complex (DISC). DISC will then 
stimulate the proteolytic maturation of pro-caspase 8 to active caspase 8. For the 
intrinsic pathway, it involves the release of cytochrome C from mitochondria to 
cytosol. Release of cytochrome C will trigger the Apaf-1-mediated activation of pro-
caspase 9 and then result in the formation of apoptosome. Both active caspase 8 and 
apoptosome can trigger the proteolytic cleavage of pro-caspase 3 to form active 
caspase Active caspase 3 is essential for late stage apoptotic response such as 
D N A fragmentation and cell surface blebbing^^ These morphological changes are 
regarded as the hallmark features of apoptosis. 
As mentioned, D N A fragmentation is one of the hallmark features of apoptosis. 
It can be utilized as an indicator for apoptosis. Double-stranded, low molecular 
weight D N A fragments and single strand breaks will be produced during the D N A 
fragmentation in apoptosis. The fragmented D N A could be recognized by terminal 
deoxynucleotidyl transferase (TdT), which catalyzes the polymerization of 
nucleotides to free 3，-0H end of the D N A . Incorporation of the fluorescence labels 
such as fluorescein isothiocyanate (FITC) can help to reveal the presence of these 
fragmented D N A . Cells which are undergoing late stage apoptosis would be 
indicated by the green fluorescence nuclei viewed under fluorescence microscope. In 
previous study, Lai et al.^^ suggested that in vitro BAM-SiPc mediated PDT could 
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induce apoptosis in HepG2 cells as shown in the T U N E L assay and the release of 
pro-apoptotic cyctochrome C to cytosol. However, it is not known whether apoptosis 
would also be triggered by in vivo PDT with BAM-SiPc under our experiment 
protocol. From the result of the present T U N E L assay, a large amount of T U N E L 
positive nuclei were observed when the HepG2 tumors were subjected to the 
combined treatment while only negligible positive signal could be detected for the 
three control groups. Thus, D N A fragmentation was only triggered by in vivo B A M -
SiPc mediated P D T but not by BAM-SiPc or illumination alone. 
At late stage apoptosis, cellular and nuclear shrinkage, chromatin condensation 
and prominent nuclear fragmentation with formation of apoptotic bodies can be 
observed94，96. From the result of H & E staining, nuclear fragmentation could only be 
observed for the PDT-treated HepG2 tumor (Fig. 3. 16). This confirmed that 
apoptosis was triggered in HepG2 tumors by in vivo BAM-SiPc mediated PDT, 
though, whether it involved the intrinsic or extrinsic pathway has yet to be 
determined. In the in vitro experiment, it was suggested that mitochondria-mediated 
apoptosis (intrinsic pathway) played a major role in switching on the apoptosis in 
HepG2 cells50. It is expected that similar signaling pathway will also be induced in 
the in vivo situation. 
4.8 Phototoxicity of BAM-SiPc was inhibited in the present of LDL 
It has been suggested that addition of LDL with PS can enhance the PS uptake 
by tumor and hence the PDT efficacy will increase^ .^ This hypothesis is supported by 
the fact that over-expression of L D L receptor is often found in cancer cells^ '^卯. 
Some researchers also believe that the enhanced photodynamic efficacy of a PS by 
L D L conjugation is due to the fact that LDL-conjugated PS would facilitate the 
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delivery to more photosensitive subcellular compartment such as mitochondria^^' 
Since the tumor uptake of BAM-SiPc was low as shown in the tissue distribution 
study (Section 3.2)，BAM-SiPc was mixed with LDL to see whether the uptake and 
hence the photodynamic activity would be increased. To our disappointment, 
phototoxicity of in vitro BAM-SiPc mediated PDT against HepG2 actually decreased 
with the addition of L D L (Fig. 3.18). One possible reason is that the uptake of B A M -
SiPc by HepG2 cells was inhibited in the presence of LDL. Another possibility is 
that the introduction of LDL altered the intracellular trafficking of BAM-SiPc such 
that it was delivered to a site less susceptible to PDT damage^ '^ ' loi. Our preliminary 
result showed that there was a 50% reduction of BAM-SiPc uptake in the presence of 
L D L (data not shown). The decrease in BAM-SiPc uptake could be either due to the 
inhibition by L D L or the covalent linkage of BAM-SiPc with the apolipoprotein of 
L D L resulted in reduced receptor recognition as suggested by Urizzi et al 
Initially, a small scale gel filtration was employed in an attempt to separate 
free BAM-SiPc and LDL-bound BAM-SiPc. It was thought that the resolution 
provided by the column was adequate to achieve the separation because the 
molecular size of L D L is much greater than that of BAM-SiPc (Molecular size of 
BAM-SiPc and L D L were 717.89 and 2.25 X 10^ respectively). The elution profile 
showed that the peaks for L D L and BAM-SiPc overlapped with each other. However, 
the peak representing free BAM-SiPc was missing in the elution profile. It might be 
possible that all BAM-SiPc was conjugated with LDL or the resolution of the gel 
filtration was not good enough to separate BAM-SiPc from LDL. To test this, a 
larger gel filtration column was used. Again, free BAM-SiPc failed to resolve from 
free L D L and L D L conjugated BAM-SiPc. It might be due to the aggregation of 
BAM-SiPc in aqueous solution. Molecular size of the aggregated BAM-SiPc could 
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be too large and exceeded the size exclusion limit (1.5 x 10^) for the G-lOO Sephadex 
gel filtration column. Hence, BAM-SiPc was eluted together with LDL in the void 
volume. So, gel filtration chromatography of the mixture of BAM-SiPc and LDL was 
unable to confirm whether LDL has been conjugated with BAM-SiPc in this 
experiment. Nevertheless, LDL was found to be unable to enhance BAM-SiPc 
uptake by HepG2 cells and hence the PDT efficacy in our study. As cancer cells 
often have extra glucose demand to fulfill their energy requirement, conjugation with 
saccharides can be a possible solution to improve the uptake of BAM-SiPc. Chen et 
al. 102 has successfully improve the tumor selectivity of porphyrin-based PS by 
conjugation with thioglucose or thiogalactose. Recently, researchers have tried to 
develop tumor specific antibody conjugated PS to increase the tumor selectivity of a 
PS because the conjugated antibody can specifically recognize the cancer cells and 
can be easily derived from antibody phage display library⑴〗.Such method may help 
to solve the problem of poor tumor selectivity of BAM-SiPc, 
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CHAPTER 5 
Conclusion and Future Perspective 
5.1 Conclusion 
Subsequent to the previous study of a novel series of silicon(IV) 
phthalocyanine derivatives, we have reported in the present study the in vitro and in 
vivo photodynamic activities of BAM-SiPc. BAM-SiPc was found to exhibit an 
extremely high phototoxicity against a wide variety of cancer cells including human 
hepatocellular carcinoma HepG2 and Hep3B, human colon adenocarcinoma HT29 
and T84. Such phenomenon could be attributed to the efficient intracellular ROS 
production by BAM-SiPc mediated PDT. A dose-dependent cytotoxicity was exerted 
by P D T with BAM-SiPc, which was also well correlated with the intracellular ROS 
production as shown by the result of D C F D A assay. 
In the in vivo study, although there was a persistent accumulation of 
BAM-SiPc in tumor for 24 h, it was disappointed to observe that the tumor 
selectivity for BAM-SiPc was low. Despite these, significant regression of HepG2 
tumor and growth retardation on HT29 tumor could be clearly seen when they were 
treated with in vivo P D T using BAM-SiPc. 
Concerning the death mechanism induced by PDT with BAM-SiPc, 
preliminary result revealed that cell cycle arrest was induced for BAM-SiPc 
concentrations between 0.005 |iM and 0.02 \xM in in vitro study. Late stage apoptotic 
or necrotic change was observed with BAM-SiPc concentrations greater than 0.02 
|iM. Results of T U N E L assay and H & E histochemical staining revealed that 
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apoptosis was also induced in HepG2 tumor when the tumor-bearing nude mice were 
treated with BAM-SiPc mediated PDT. 
The phototoxicity against HepG2 cells was reduced in the presence of L D L 
which could be due to the inhibition of cellular uptake of BAM-SiPc by LDL. 
However, it has not yet known whether the reduced uptake was due to competitive 
inhibition of L D L or reduced receptor recognization because of the altered chemical 
structure by the conjugation to apolipoprotein B. Identification of the presence of 
LDL-conjugated BAM-SiPc by means of gel filtration chromatography failed. It is 
because L D L could not be separated from BAM-SiPc. BAM-SiPc aggregated 
together and was eluted in void volume with LDL. Owing to the fact that the tumor 
selectivity of BAM-SiPc is low, it is necessary to search for another biomolecule to 
conjugate with BAM-SiPc or a chemical modification of BAM-SiPc so that the 
BAM-SiPc uptake by tumor can be enhanced. 
In the present study, it was shown that BAM-SiPc can be a potential 
phthalocyanine-based agent used in clinical PDT for cancer treatment. On the other 
hand, the present study also provides the foundation for the future development of 
novel PS, highly active in terms of photodynamic activities but with minimal side 
effect. 
5.2 Future perspective 
• Eradication ofHT29 tumor by repeated PD T treatment with BAM-SiPc 
In in vivo PDT, growth retardation on HT29 tumor was observed for 10 days 
when a single dose of BAM-SiPc was administered to the tumor-bearing nude mice. 
It is worth to study whether complete eradication of HT29 tumor can be achieved if ^  
repeated treatment of BAM-SiPc mediated PDT is applied at time before the normal 
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growth of the tumor resumed. 
• Enhance BAM-SiPc uptake by conjugating with alternate biomolecules 
Since L D L failed to enhance the PDT efficacy of BAM-SiPc, it is necessary to 
search for other biomolecules such as glucose or insulin^ ^ for conjuga tion with 
BAM-SiPc in order to enhance the tumor uptake of BAM-SiPc and hence the PDT 
efficacy of BAM-SiPc in an in vivo system. 
• Investigation on the intracellular signaling pathway involved in BAM-SiPc 
mediated PDT induced cell death 
PI staining for cell cycle distribution after PDT with BAM-SiPc should be 
repeated to confirm the results because cell cycle arrest found in the present study 
was only a preliminary finding. If it is confirmed, Western blotting for the cell cycle 
proteins such as cdk2, cyclin D and cyclin E should be done to unveil the possible 
intracellular signaling events involved in the cell death induced by in vitro PDT. 
P D T can drastically increase the oxidative stress inside the cells. It has been 
reported that the intracellular oxidative stress induced by PDT can lead to oxidation 
or carbonylation of cellular proteins^ '^卯.These oxidized or carbonylated proteins can 
serve as a signal that triggers apoptosis. Therefore, the amount of oxidized protein 
formed after P D T with BAM-SiPc can be determined to see if oxidized protein plays 
an important role in P D T induced cell death. Proteomic analysis on the differential 
expression of oxidized protein will also provide information on the identity of those 
oxidized proteins which trigger cell death. 
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• Identification of the metabolite ofBAM-SiPc 
In the present study, the identity of metabolite was not yet known. Liquid 
Chromatography-Mass Spectrometry (LC-MS) could be used so that the chemical 
structure of the metabolite can be speculatedi04. Based on the chemical structure of 
the metabolite, we can get an insight on the pathway involved in metabolism of 
BAM-SiPc. 
• Anti-tumor immunity related to BAM-SiPc mediated PDT 
PDT can kill the cancer cells by directly inducing cell death and/or shutting 
down the tumor vasculature which deprives the tumor oxygen and nutrients 】风 i05 
Recently, there is much evidence showing that the immune response subsequent to 
PDT treatment also contributes to cancer cell death. It has been suggested that the 
apoptotic or necrotic cells formed by PDT will trigger the acute inflammatory 
response. Neutrophil infiltration and cytokine production such as IL-6, ILIO, 
tumor-necrosis factor-a (TNF-a) are the events which have been linked to tumor cell 
death 106. In the future, study on the anti-tumor immunity induced by BAM-SiPc 
mediated PDT will provide insights on whether acute inflammatory responses 
mentioned above are induced by BAM-SiPc alone or PDT with BAM-SiPc. 
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